

WHIM Syndrome-linked CXCR4 mutations drive osteoporosis

Adrienne Anginot, Julie Nguyen, Zeina Abou Nader, Vincent Rondeau, Amélie Bonaud, Maria Kalogeraki, Antoine Boutin, Julia Lemos, Valeria Bisio, Joyce Koenen, et al.

▶ To cite this version:

Adrienne Anginot, Julie Nguyen, Zeina Abou Nader, Vincent Rondeau, Amélie Bonaud, et al.. WHIM Syndrome-linked CXCR4 mutations drive osteoporosis. Nature Communications, 2023, 14 (1), pp.2058. 10.1038/s41467-023-37791-4 . hal-04077290

HAL Id: hal-04077290 https://hal.science/hal-04077290

Submitted on 21 Apr 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

- 1 Using a mouse model harboring a WHIM Syndrome-linked gain-of-function CXCR4 mutation and
- 2 bone marrow samples from WHIM patients, the authors show that proper CXCR4 signaling
- 3 termination is essential for bone tissue homeostasis.

1	WHIM Syndrome-linked CXCR4 mutations drive osteoporosis
2	Adrienne Anginot ^{1,2,3,#} , Julie Nguyen ^{2,4,#} , Zeina Abou Nader ^{1,2,3,#} , Vincent Rondeau ^{1,2,3} , Amélie
3	Bonaud ^{1,2,3} , Maria Kalogeraki ^{1,2,3} , Antoine Boutin ⁵ , Julia Lemos ^{1,2,3} , Valeria Bisio ^{1,2,3} , Joyce
4	Koenen ^{2,4} , Léa Sakr ⁶ , Amandine Picart ⁶ , Amélie Coudert ⁶ , Sylvain Provot ⁶ , Nicolas Dulphy ^{1,2,3} ,
5	Michel Aurrand-Lions ^{2,7} , Stéphane J.C. Mancini ^{2,7} , Gwendal Lazennec ^{2,8} , David H.
6	McDermott ⁹ , Fabien Guidez ^{3,10} , Claudine Blin-Wakkach ⁵ , Philip M. Murphy ⁹ , Martine Cohen-
7 8	Solal ⁶ , Marion Espéli ^{1,2,3,£} , Matthieu Rouleau ^{5,£} , and Karl Balabanian ^{1,2,3,*}
9	¹ Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160, Paris, France.
10	² CNRS, GDR3697 "Microenvironment of tumor niches", Micronit, France.
11	³ OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis,
12	Paris, France.
13	⁴ Inflammation, Chemokines and Immunopathology, INSERM, Université Paris-Saclay,
14	Clamart, France.
15	⁵ Université Côte d'Azur, CNRS, LP2M, Nice, France.
16	⁶ Université Paris Cité, BIOSCAR Inserm U1132, Department of Rheumatology and Reference
17	Center for Rare Bone Diseases, AP-HP Hospital Lariboisière, Paris, France.
18	⁷ Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
19	⁸ CNRS, SYS2DIAG-ALCEDIAG, Cap Delta, Montpellier, France.
20	⁹ Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of
21	Allergy and Infectious Diseases, NIH, Bethesda, MD.
22	¹⁰ Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1131, Paris, France.
23	[#] AA, JN and ZA-N: these authors contributed equally.
24	[£] ME and MR: these authors contributed equally.
25 26	*Correspondence & lead contact: karl.balabanian@inserm.fr.

27	Abbreviations: BMSC: Bone marrow stromal cell; C-tail: Carboxyl-terminal tail; HSPC:
28	Hematopoietic stem and progenitor cell; MFI: Mean fluorescence intensity; OBL: Osteoblast;
29	OCL: Osteoclast; Ocn: Osteocalcin; OPC: Osteoblastic progenitor; Opn: Osteopontin; Osx:
30	Osterix; SLAM: Signaling lymphocyte activation molecule; SSC: Skeletal stromal/stem cell;
31	WS: Warts, Hypogammaglobulinemia, Infections and Myelokathexis Syndrome.

33 ABSTRACT

34 WHIM Syndrome is a rare immunodeficiency caused by gain-of-function CXCR4 mutations. 35 Here we report a decrease in bone mineral density in 25% of WHIM patients and bone defects 36 leading to osteoporosis in a WHIM mouse model. Imbalanced bone tissue is observed in mutant 37 mice combining reduced osteoprogenitor cells and increased osteoclast numbers. 38 Mechanistically, impaired CXCR4 desensitization disrupts cell cycle progression and 39 osteogenic commitment of skeletal stromal/stem cells, while increasing their pro-40 osteoclastogenic capacities. Impaired osteogenic differentiation is evidenced in primary bone 41 marrow stromal cells from WHIM patients. In mice, chronic treatment with the CXCR4 42 antagonist AMD3100 normalizes in vitro osteogenic fate of mutant skeletal stromal/stem cells 43 and reverses in vivo the loss of skeletal cells, demonstrating that proper CXCR4 desensitization 44 is required for the osteogenic specification of skeletal stromal/stem cells. Our study provides 45 mechanistic insights into how CXCR4 signaling regulates the osteogenic fate of skeletal cells 46 and the balance between bone formation and resorption.

47

48 <u>Keywords:</u> Skeletal stromal/stem cell; Bone marrow; CXCR4 signaling; Osteogenesis; WHIM
49 Syndrome; Osteoporosis.

50

51

53 **INTRODUCTION**

54 The bone marrow (BM) is a complex structural and primary immune organ whose development and maintenance depend on multiple cell types including cells of the hematopoietic lineage like 55 56 hematopoietic stem and progenitor cells (HSPCs), but also vascular cells and numerous skeletal 57 cells encompassing BM stromal cells (BMSCs), skeletal progenitor/precursor cells as well as 58 bone-making osteoblasts (OBLs)^{1,2}. Together these cells compose specialized microanatomical structures called "niches" that sustain their survival and differentiation³⁻⁹. For 59 60 instance, the HSPC niches are thought to be composed of perivascular stromal units associated with sinusoids and arterioles¹⁰⁻¹⁵. Bone and adipose cells are thought to derive from subsets of 61 BMSCs that are located near blood vessels and function as skeletal stromal/stem cells (SSCs)¹⁶⁻ 62 ¹⁹. However, the exact localization, composition and crossover of these niches in relation with 63 64 bone function are not vet established. Bone tissue homeostasis relies on the balance between 65 formation and resorption of bone matrix mediated by effector cells that derive from SSCs and 66 HSPCs respectively. Disequilibrium of this balance can lead to diseases such as osteoporosis 67 or osteopetrosis. In such a landscape, SSCs are key players: not only they give rise to OBLs but 68 they also contribute to perivascular structures important for HSPCs²⁰⁻²⁸. Understanding how 69 SSCs maintain their identity, achieve plasticity and support hematopoiesis in adult BM is thus an important emerging field^{3,6,9,12,29}. Recently, Ambrosi and coll. showed that intrinsic ageing 70 71 of SSCs skews skeletal and hematopoietic lineage outputs, leading to fragile bones³⁰. Moreover, 72 Jeffery and coll. reported how BM and periosteal SSCs contribute to bone maintenance and 73 repair³¹. However, both extrinsic and intrinsic mechanisms regulating their fate remain 74 incompletely understood.

In adult BM, signaling by the G protein-coupled receptor CXCR4 on HSPCs in response to stimulation by the chemokine CXCL12/Stromal cell-derived factor-1, produced by BMSCs constitutes a key pathway through which the stromal niches and HSPCs communicate³²⁻³⁷.

78 Conditional ablation of Cxcl12 from perivascular stromal cells or OBLs demonstrated that 79 HSCs occupy a perivascular but not an endosteal niche^{21,38}, whereas targeted deletion of *Cxcl12* 80 from BM stromal cells has allowed the identification of specialized niches supporting leukemia 81 stem cell maintenance³⁹. Both Cxcr4 and Cxcl12 are broadly expressed by non-hematopoietic 82 tissues and cell types and have multifunctional roles beyond hematopoiesis. Since mice 83 deficient for Cxcr4 or Cxcl12 die perinatally, our understanding of the role of the Cxcl12/Cxcr4 84 axis in regulating the BM ecosystem is mostly based on relatively selective loss-of-function 85 models^{21,40-44}. Conditional inactivation of *Cxcl12* or *Cxcr4* in paired-related homeobox gene 1 86 (Prx1)- or osterix (Osx)-expressing cells, *i.e.* respectively multipotent mesenchymal 87 progenitors or osteoprogenitor cells (OPCs) and descendant OBLs, was associated with reduced 88 postnatal bone formation, suggesting a positive regulatory role of this pair in OBL development 89 and/or function^{21,43,44}. Single cell transcriptomics recently suggested heterogeneity within adult 90 Cxcl12- or Leptin-receptor (LepR)-expressing mesenchymal cells poised to undergo either 91 adipogenic or osteogenic specification^{45,46}. However, it is still unclear whether and how Cxcr4 92 signaling regulates intrinsically osteogenic specification of skeletal cells.

93 Here, we addressed this point using as a paradigm the WHIM Syndrome (WS), a rare 94 immunodeficiency caused by viable inherited heterozygous gain-of-function mutations in 95 CXCR4 affecting homologous desensitization of the receptor, thus resulting in enhanced 96 signaling following CXCL12 stimulation, defective lymphoid differentiation of HSPCs and 97 reduced blood leukocyte numbers⁴⁷⁻⁵⁰. Taking advantage of a mouse strain that harbors the naturally occurring WS-linked heterozygous CXCR4^{S338X} mutation (Cxcr4^{+/1013}, +/1013)⁵¹⁻⁵⁴, 98 99 and of human BM samples from WS donors and clinical data from 19 WS patients, we 100 investigated whether WS mutations affect the SSC landscape with a particular attention given 101 to the bone fraction. WS-linked CXCR4 mutations were associated with reduced bone mass in 102 mice and humans. In mice, this relied on impaired CXCR4 desensitization that disrupts cell

- 103 cycle progression and osteogenic commitment of SSCs, while paradoxically increasing the pro-
- 104 osteoclastogenic capacities of these cells. Impairment in osteogenic potential was also
- 105 evidenced in BMSCs from WS patients. Thus, proper CXCR4 desensitization is required for
- 106 the osteogenic specification of bone SSCs.

108 **RESULTS**

109 WS-linked CXCR4 mutations are associated with reduced bone mass in mice and humans 110 Following CXCL12 stimulation, β -arrestins are recruited to the carboxyl-terminal tail (C-tail) 111 domain of CXCR4, precluding further G-protein activation (*i.e.* desensitization) and leading to 112 receptor internalization⁵⁵. Both processes are dysregulated in WS most often due to autosomal-113 dominant gain-of-function mutations that result in the distal truncation of the C-tail of CXCR4 114 and a desensitization-resistant, hyperactive receptor⁵⁶. Although the impact of these WS mutations on immune cells is currently being understood^{51-54,57}, nothing is known about their 115 116 impact on the skeletal landscape. Bone mineral density (BMD) values were measured in 19 117 patients with WS for lumbar spine and femoral neck by total body dual-energy X-ray 118 absorptiometry. BMD T- and Z-scores were found to be low at least in one site in five patients 119 (Table 1). Likewise, this was evidenced in adult (8-12-week-old) Cxcr4¹⁰¹³-bearing (i.e. heterozygous [+/1013] and homozygous [1013/1013]) mice, as compared to $Cxcr4^{+/+}$ (WT) 120

mice. Analyses of lumbar spine revealed decreased BMD values in mutant mice, in a $Cxcr4^{1013}$ allele dose-dependent manner (Fig. 1A). Micro-computed tomography (µCT) analyses further unraveled a reduction in trabecular and cortical bone in mutant mice (Fig. 1B). In mutant

femurs, there was a reduction in the trabecular bone density that followed a $Cxcr4^{1013}$ allele copy number-dependent pattern. This was characterized by a significant decrease in bone volume and trabecular numbers, while the trabecular separation was increased compared to WT

127 mice (Fig. 1C). The cortical bone volume and thickness were also affected (Fig. 1B and 1D).

This gene-dependent reduction was observed among both female and male mutant mice.
Histomorphometric analyses confirmed decreased bone volume and trabecular numbers in
mutant mice as shown by toluidine blue and osteopontin (Opn) staining (Fig. 1E and 1F).
Strikingly, staining for Alcian Blue and perilipin that are used for chondrocyte and adipocyte

132 identification respectively, were unaltered in mutant bone (Fig. 1G and 1H). Consistently, the

thickness of the growth plate as well as the adipocyte content were similar in mice carrying the *Cxcr4* mutation compared to WT ones (Fig. 1I and 1J), thus suggesting that Cxcr4 specifically regulates the osteogenic fate in adults. Moreover, adult mutant mice did not exhibit significant changes of body size or weight (Fig. 1K), indicating that the *Cxcr4* mutation likely does not alter the skeletal growth. Overall, these findings revealed an osteopenic skeleton in *Cxcr4¹⁰¹³*bearing mice and low BMD in 25% of WS patients.

139

140 Reduction of skeletal stromal cells in *Cxcr4¹⁰¹³*-bearing mice

141 We then evaluated by flow cytometry the bone composition of WT and mutant mice with a 142 focus on skeletal cells that encompass notably SSCs, OPCs and OBLs⁵⁸. Long bones were 143 flushed and then digested. Total stromal cells in the bone fraction were identified as negative 144 for CD45, Lineage (including Ter119), c-Kit and CD71 expression as previously reported^{12,59}. 145 Endothelial cells were excluded based on CD31 expression. Two distinct CD51⁺ stromal cell 146 subsets were identified based on Sca-1 and PDGFR α : SSCs (Sca-1+PDGFR α +) and more 147 differentiated OPCs (Sca-1⁻PDGFR $\alpha^{+/-}$) (Fig. 2A). We consider Sca-1⁺PDGFR α^{+} cells at the 148 top of the hierarchy based on previous works that indicated a highest CFU-F clonogenic potential of these cells as compared to Sca-1⁻PDGFR α^+ cells^{12,28,31,60}. We observed a significant 149 150 decrease of the numbers of OPCs, and to a lesser extent of SSCs, that followed a Cxcr4¹⁰¹³ 151 allele dose-dependent pattern (Fig. 2B), thus reinforcing that the landscape of the bone stroma 152 is altered in *Cxcr4*¹⁰¹³-bearing mice.

We next examined *in vitro* the function of the signaling trio formed by Cxcl12 and its two receptors Cxcr4 and Ackr3 in skeletal cells. Membrane expression of Cxcr4 and Ackr3 was similar between WT and mutant skeletal cells including SSCs (Fig. S1A and S1B). However, +/1013 and 1013/1013 SSCs displayed both impaired Cxcr4 internalization following Cxcl12 stimulation as well as increased Cxcl12-mediated chemotaxis that was abolished by the specific 158 Cxcr4 antagonist AMD3100 (Fig. S1C and S1D). These dysfunctions likely relied on the 159 enhanced signaling properties of the truncated Cxcr4 receptor as revealed by Erk PhosphoFlow 160 analyses (Fig. S1E). Combined with the apparent preserved capacity of Ackr3 to bind and 161 internalize Cxcl12 *in vitro* (Fig. S1F and S1G), these findings indicated a functional expression 162 of the desensitization-resistant C-tail-truncated Cxcr4¹⁰¹³ receptor on SSCs. Abnormal Cxcr4 163 signaling was not associated with changes in apoptosis of SSCs (Fig. S1H).

164 To determine whether reduction of bone content in Cxcr4¹⁰¹³-bearing mice resulted 165 from defects intrinsic to skeletal cells and/or an alteration of the hematopoietic (or another non-166 stromal) system, we performed reciprocal long (16 weeks)- and short (3 weeks)-term BM 167 reconstitution experiments. First, BM cells from WT CD45.1⁺ mice were transplanted into lethally irradiated 8-wk old CD45.2⁺ WT or mutant (+/1013 and 1013/1013) mice (Fig. 2C). 168 Sixteen weeks later, mutant recipients exhibited CD45.1⁺ chimerism in hematopoietic 169 170 compartments similar to those of WT recipients (Fig. 2D) but displayed reduced numbers of 171 skeletal cells including SSCs and OPCs (Fig. 2E). Confocal imaging and µCT analyses 172 confirmed that transplantation of WT BM was not sufficient to rescue the trabecular network 173 in mutant recipients (Fig. 2F-I). This was also evidenced three weeks after WT BM 174 transplantation (Fig. 2G). Although we cannot formally exclude that WT hematopoietic cells 175 may be able to rescue the reduced trabecular bone content in mutant mice earlier in 176 development, these results suggested that skeletal cell-autonomous Cxcr4 regulation contributes to the persistent bone defects in adult *Cxcr4¹⁰¹³*-bearing mice. We then performed 177 178 reverse chimeras in which irradiated 8-wk old CD45.1⁺ WT mice were reconstituted with WT, 179 +/1013 or 1013/1013 CD45.2⁺ BM (Fig. 3A). Sixteen weeks later, CD45.2⁺ chimerism of LT-180 HSCs and leukocytes were decreased respectively in BM and blood of CD45.1⁺ WT recipients 181 engrafted with mutant BM, confirming the impaired reconstitution capacity of mutant HSCs 182 (Fig. 3B and ⁴⁹). There were significantly lower numbers of skeletal cells and defective trabecular bone content in $Cxcr4^{1013}$ -bearing BM-chimeric mice compared to WT chimeras as early as 3 weeks post-transplantation (Fig. 3C-G), thereby indicating cell-extrinsic Cxcr4mediated regulation of the skeletal landscape. Likewise, cortical bone content was slightly affected (Fig. 3H and 3I). Altogether, these findings suggest that impaired Cxcr4 desensitization in both skeletal and hematopoietic cells have combinatorial effects on bone landscape dysregulation in adult $Cxcr4^{1013}$ -bearing mice.

189

190 Increased bone resorption and reduced bone formation in *Cxcr4*¹⁰¹³-bearing mice

191 Bone is maintained by coupled activities of bone-forming OBLs and bone-resorbing osteoclasts 192 (OCLs). Alterations in bone balance can result in pathologic bone loss and osteoporosis. This 193 led us to investigate whether the gain-of-*Cxcr4*-function mutation modulates the OBL/OCL 194 balance. First, we analyzed bone resorption by quantifying OCL numbers in mice using Tartrate 195 Resistant Acid Phosphatase (TRAP) staining⁶¹. We observed increased OCL surface (Oc.S/BS) 196 and number (Oc.N/BV) in mutant mice compared to WT ones (Fig. 4A and 4B). To determine 197 whether the increased bone resorption in mutant mice resulted from OCL-intrinsic defects, we 198 performed in vitro OCL differentiation from BM cells in the presence of M-Csf and Rank-L 199 and tested their bone resorption capacity. Similar OCL numbers and bone matrix resorption 200 activities were observed among WT and mutant cultures (Fig. S2A and S2B), suggesting 201 preserved intrinsic capacities of mutant BM myeloid cells to differentiate in vitro into functional 202 OCLs. Congruent with this, we observed no changes in expression levels of osteoclastogenic 203 genes in mutant cultures compared to WT ones (Fig. S2C). These findings indicate that the 204 Cxcr4 mutation does not affect in vitro OCL differentiation and function but suggest that 205 osteoclastogenesis and increased bone resorption in mutant mice may be promoted by the BM 206 environment.

 $Cxcr4^{1013}$ -bearing mice exhibited similar bone formation as revealed by osteoid surface 207 208 (OS/BS) and osteoblast surface (Obl.S/BS) compared to WT mice (Fig. 4C). Dynamic 209 parameters of in vivo bone formation were also assessed by quantifying bone surfaces labelled 210 with tetracycline and calcein. Total and double labelled surfaces were lower in mutant than WT mice (Fig. 4D), whilst mineral apposition rate (MAR) were similar in WT and Cxcr4¹⁰¹³-211 212 bearing mice (Fig. 4E). Overall, bone formation rate (BFR/BS) was significantly reduced in 213 mutant mice (Fig. 4E). This suggests a decrease in bone formation related to a lower number 214 of OPCs and OBLs with maintained activity of individual OBL. In line with preserved intrinsic 215 bone formation capacities of active osteoblastic lineage cells in mutant mice, high-throughput 216 RNA sequencing (RNA-seq) and qPCR analyses of OPC bulk-sorted by flow cytometry from 217 the bone fraction on the basis of the CD51 and Sca-1 markers (Fig. 2A) highlighted a gene 218 signature with preserved mineralized matrix potential in mutant OPCs (Fig. 4F-H and S2D-F). 219 In agreement, sorted OPCs from mutant mice were as efficient as WT ones in vitro at producing 220 differentiated OBLs and mineralized nodules after 14- or 21-days culture in osteogenic medium 221 as determined by Alkaline phosphatase (Alp) and Alizarin Red (AR) staining 222 respectively^{24,60,62,63} (Fig. 4I and S2G). This was confirmed by qPCR analyses with no changes 223 in expression of genes encoding osteogenic regulators in mutant cultures (Fig. S2H). These 224 findings suggest reduced osteogenic lineage commitment in *Cxcr4*¹⁰¹³-bearing mice. Given that 225 osteogenic cells support osteoclastogenesis through the production of factors such as Rank-L 226 $(Tnfsf11)^{64}$, we questioned our RNAseq data on the related gene expression profile in mutant 227 and WT OPCs. No major changes in expression levels of pro-osteoclastogenic or anti-resorptive 228 genes were revealed in mutant OPCs (Fig. 4J and 4K).

To investigate whether increase in OCLs in mutant mice is linked to an altered stromal BM environment, we sought to set up co-culture experiments between *in vitro* expanded osteogenic cells carrying or not the *Cxcr4* mutation and WT OCL precursors, *ie.*, BM CD11b⁺

232 myeloid cells as reported⁶⁵. We showed that mutant osteogenic cells promoted exacerbated 233 OCL differentiation compared to WT cells (Fig. 4L). Soluble factors seem not to be sufficient 234 as the supernatants of such stimulated expanded osteogenic cells (WT or mutant) did not induce 235 OCL differentiation. Additionally, transcriptomic analyses of stimulated osteogenic cells 236 carrying or not the Cxcr4 mutation did not reveal any major changes in expression levels of 237 master genes regulating osteoclastogenesis (Fig. 4M). These findings suggest a juxtacrine 238 function of osteogenic cells toward OCL differentiation that likely relies on direct interactions 239 between both cell types and involves the Cxcl12/Cxcr4 axis.

240 Taken as a whole, our findings suggest that the hematopoietic contribution to bone loss in Cxcr4¹⁰¹³-bearing mice likely involves dysregulation of the OCL compartment regardless of 241 242 their activity. The overall decrease in bone mass in mutant mice may involve modulation of 243 osteogenic and osteoclastogenic components with decreased bone formation and increased 244 bone resorption. Bone remodeling involves a tight regulation of opposite processes leading to bone resorption and bone formation^{66,67}. The observation that immature and mature osteogenic 245 246 cells, *i.e.*, OPCs and OBLs, displayed preserved intrinsic functions led us to study the early 247 differentiation process of the osteolineage.

248

249 Impaired osteogenic specification of *Cxcr4¹⁰¹³*-bearing skeletal stromal cells

We thus investigated the intrinsic characteristics of SSCs carrying the *Cxcr4* mutation. Undifferentiated stem cells are characterized by their slow cell cycle progression in unperturbed conditions^{9,68}. This led us to interrogate by flow cytometry the cycling status of SSCs from the bone fractions of *Cxcr4¹⁰¹³*-bearing mice by performing DAPI/Ki-67 staining. A slight but significant increase in the frequency of cells in the quiescent G0 state (DAPI^{low}Ki-67⁻) was observed among 1013/1013 SSCs but not in the more differentiated osteoblastic pool (Fig. 5A). The turnover of those cells was then studied by performing a 12-day BrdU pulse-chase assay

in vivo (Fig. 5B). Consistent with previous studies^{28,69}, the fraction of BrdU⁺ cells in WT SSCs reached ~5%, while we observed a $Cxcr4^{1013}$ allele copy number-dependent reduction in BrdU incorporation within mutant SSCs. No changes were observed among mutant OPCs compared to WT ones. Combined to reduced SSC and OPC numbers in mutant bones (Fig. 2B), these findings are suggestive of reduced cycling and osteogenic differentiation capacities of $Cxcr4^{1013}$ -bearing SSCs.

263 To gain further mechanistic insights, we investigated the impact of the gain-of-Cxcr4-264 function on the molecular identity of SSCs by performing RNA-seq analyses of bulk-sorted 265 SSCs from the bone fraction of WT and mutant mice. Biological processes related to cell cycle 266 and osteogenic differentiation were significantly modulated in 1013/1013 SSCs as determined 267 by Gene set enrichment analysis (GSEA) (Fig. 5C). The signature for genes related to cell cycle 268 progression and regulation was reduced in 1013/1013 SSCs (Fig. S3A and S3B). Likewise, 269 genes related to osteogenic differentiation appeared to be decreased in mutant SSCs (Fig. 5D 270 and 5E). In contrast, key genes involved in both adipogenesis and chondrogenesis were not 271 differentially expressed in mutant SSCs (Fig. S3C). These results were confirmed by 272 microfluidic-based multiplex gene expression analyses (Fig. 5F and 5G and Fig. S3D), thus 273 suggesting that proper Cxcr4 signaling is required for regulating osteogenic specification of 274 SSCs. No changes in expression levels of pro-osteoclastogenic genes were detected in mutant SSCs compared to WT ones (Fig. 5H-J). Therefore, these results unravel a Cxcr4-mediated 275 276 transcriptional signature in Cxcr4¹⁰¹³-bearing SSCs suggestive of impaired cell cycle 277 progression and defective osteogenic specification.

In adult BM, the majority of OBLs derives from OPCs identified by markers such as osterix $(Osx)^{3,9,17,28,70-72}$. They are predominantly found close to the growth plate cartilage along trabecular bone of the primary spongiosa, and along the metaphyseal cortical bone^{70,71,73}. We thus examined whether the gain-of-*Cxcr4*-function mutation alters the number of Osx-positive OPCs by immunodetection on bone sections. We found fewer Osx-positive OPCs in mutant bones compared to WT (Fig. 5K and 5L). This decrease was confirmed by flow cytometry in the flushed stromal marrow fraction that encompasses Sca-1-negative and PDGFR α -positive early OPCs with multipotent adipo/osteogenic potential (Fig. 5M)^{28,45,70}. Together, these data suggest that the decrease in early and committed OPCs in mutant mice may arise from a defect in osteogenic specification of BM-residing SSCs.

288

289 Cxcr4 desensitization intrinsically regulates *in vitro* the osteogenic differentiation of 290 skeletal stromal cells

291 To assess whether Cxcr4 desensitization could regulate SSC fate toward the osteogenic lineage 292 in a cell-intrinsic manner, we first compared in vitro the clonogenic capacities of WT and 293 mutant total skeletal cells. There was a significant decrease in the number of colony-forming units-fibroblast (CFU-Fs) in mutant bone cell cultures that followed a Cxcr4¹⁰¹³ allele copy 294 295 number-dependent pattern (Fig. 6A). These results suggested that impaired Cxcr4 signaling 296 might affect in vitro overall SSC numbers as well as their proliferation. To test this, we 297 evaluated by flow cytometry cell cycle and proliferation of SSCs expanded *in vitro* using BrdU, 298 Cell Trace Violet (CTV) and DAPI/Ki-67 staining. By day 5 after BrdU pulse, we observed a Cxcr4¹⁰¹³ allele dose-dependent reduction in BrdU incorporation within mutant SSCs as 299 300 compared to WT (Fig. 6B, left panel). Consistently, the fraction of proliferating CTV^{low} cells 301 was reduced among mutant SSCs three days after loading (Fig. 6B, right panel). This altered 302 proliferative capacity of Cxcr4¹⁰¹³-bearing SSCs was associated with a slight but significant 303 increase in proportions of SSCs in the quiescent G0 state (DAPIlowKi-67-), whereas no changes 304 in apoptosis level were observed (Fig. 6C). This might account for the increased doubling time 305 of mutant SSCs as well as their overall reduced number during the culture (Fig. 6D). Altogether,

these findings suggest that Cxcr4 desensitization is required *in vitro* for appropriate SSC
 proliferation, expansion and likely maintenance.

308 Next, we investigated *in vitro* the osteogenic potential capacities of $Cxcr4^{1013}$ -bearing 309 SSCs^{62,63}. Staining of *in vitro* differentiated osteogenic cells and mineralization capacities by 310 Alp and AR was significantly reduced in cultures from mutant SSCs in an allele dose-dependent 311 manner (Fig. 6E and 6F, upper panels). Real-time PCR analysis revealed decreased expression 312 of genes encoding osteogenic regulators in mutant cultures (Fig. 6G, upper panels). This was 313 more marked for early osteogenic genes downstream the master regulator Runx2 such as Osx 314 and particularly evident in the culture of 1013/1013 SSCs, thus suggesting defects at very early 315 stages in the osteogenic differentiation process. In line with this, higher mRNA expression of 316 Scal and $Pdgfr\alpha$ was observed in mutant cultures three weeks after pro-osteogenic condition 317 initiation (Fig. S4A, left panel). Consistent with the results obtained with Alcian blue and 318 Perilipin staining on bone sections (Fig. 1G and 1H), Cxcr4¹⁰¹³-bearing SSCs differentiated into 319 adipocytes or chondrocytes similarly to WT SSCs when cultured in vitro with adipogenic or 320 chondrogenic media respectively (Fig. S4B and S4C). Collectively, these data reveal in vitro a 321 selective reduction of the osteogenic differentiation capacity of mutant SSCs, and further 322 confirm a pivotal role for Cxcr4 desensitization in regulating this process at very early stages.

323

Normalization of Cxcr4 signaling rescues the osteogenic properties of *Cxcr4¹⁰¹³*-bearing mouse skeletal cells

We then determined whether targeting Cxcr4 signaling would counteract the defective osteogenic fate of mutant SSCs. First, we assessed *in vitro* the impact of adding AMD3100 every 2 days on the osteogenic capacities of SSCs. AMD3100-mediated inhibition of Cxcr4 signaling in WT SSCs led to slight changes including decreased numbers of osteogenic cells (Fig. 6E and 6F, lower panels). By contrast, mutant cultures were highly sensitive to AMD3100

treatment as shown by the normalization of Alp and AR colorations 14 and 21 days after differentiation respectively (Fig. 6E and 6F) and of the expression of *Sca1* and *Pdgfra* (Fig. S4A). Moreover, AMD3100-mediated reversion of defective osteogenesis within *Cxcr4¹⁰¹³*bearing SSC cultures was associated with normalized gene expression of osteogenic master regulators (Fig. 6G, lower panels), thus unravelling that Cxcr4 desensitization intrinsically regulates *in vitro* the osteogenic differentiation of SSCs.

337 Then, we assessed the impact of daily intraperitoneal injections for 3 weeks of 5 mg/kg 338 AMD3100 on the bone landscape in adult WT and mutant mice (Fig. 7A). Cxcr4 inhibition 339 decreased slightly the number of WT skeletal cells, and notably OPCs, in the bone fraction (Fig. 340 7B). In line with this, Opn-stained femoral sections revealed minor alterations in the 341 architecture of WT mice trabecular microstructures upon treatment (Fig. 7C). This was 342 extended to lumbar spine that displayed roughly normal BMD values in treated vs untreated 343 WT mice (Fig. 7D). In 1013/1013 mice, chronic AMD3100 treatment reversed the quantitative 344 defect in skeletal cells by normalizing the numbers of SSCs and OPCs (Fig. 7B). This was not 345 evidenced in +/1013 mice nor associated with a rescue of the trabecular or the cortical network 346 (Fig. 7C and 7E). However, AMD3100 treatment ameliorated slightly but significantly BMD 347 values of lumbar spine in mutant mice (Fig. 7D), suggesting a correcting effect of Cxcr4-348 dependent signaling dampening on other cell types and mechanisms such as OCLs or LepR-349 positive BM SSCs as recently reported³¹. Therefore, these data suggest that integrity of Cxcr4 350 signaling is required for maintaining the osteogenic properties of skeletal cells.

351

352 BM stromal cells from WS patients displayed in vitro impaired osteogenic capacities

Finally, we sought to investigate if CXCR4 desensitization was mechanistically involved in regulating *in vitro* the multilineage differentiation capacities of human primary BMSCs that

355 constitute a heterogeneous population containing skeletal progenitors¹⁸. To this end, we

356 analyzed BM samples from two unrelated patients with WS and carrying the heterozygous CXCR4^{R334X} mutation. In parallel, we expanded *in vitro* BMSCs from BM aspirates of seven 357 358 independent healthy donors. All culture-expanded BMSCs were negative for the CD45 359 hematopoietic marker lineage but positive for CD73, CD90 and CD105, a combination of 360 markers that are indicative of stromal/fibroblastic cells (Fig. S5A). Both healthy and WS 361 BMSCs were spindle shaped and fibroblast-like cells and had the ability to form stromal 362 colonies as shown by CFU-F assay (Fig. S5B and S5C). CXCL12 and its two receptors CXCR4 363 and ACKR3 were readily detectable and found at similar levels between cultured healthy and 364 WS BMSCs (Fig. S5D-F). However, real-time PCR analyses revealed decreased expression of 365 genes encoding early and late osteogenic master regulators in WS BMSC cultures compared to 366 healthy controls (Fig. 8A). In line with this, when equal numbers of cells were plated at the start 367 of the assay, WS BMSCs exhibited defective capacities to generate in vitro osteogenic progeny 368 in contrast to BMSCs harvested from healthy donors (Fig. 8B). In contrast, WS BMSCs were 369 as efficient as control cells to generate adipocytes in appropriate culture media condition (Fig. 370 8C). Therefore, these findings suggest that *in vitro* osteogenic differentiation of human primary 371 BMSCs requires proper CXCR4 signaling regulation.

DISCUSSION

374 In this study, we investigated the regulatory role of CXCR4 signaling termination in the selfrenewal and differentiation capacities of adult BM-residing SSCs. We used a knock-in mouse 375 376 model expressing a naturally occurring WS-linked heterozygous gain-of-function Cxcr4 377 mutation as well as human BM samples and clinical data from healthy and WS donors. We 378 demonstrated a mutated allele dose-dependent effect of the WS-linked Cxcr4¹⁰¹³ mutation on 379 trabecular bone microstructures mimicking an osteoporotic-like syndrome, evidenced as well 380 in one quarter of WS patients. This Cxcr4-mediated reduction in bone content involved both 381 cell-autonomous and cell-extrinsic defects in SSCs (Fig. 8D). Indeed, we provided 382 unanticipated evidence that Cxcr4 desensitization is intrinsically required for regulating in vitro 383 the quiescence/cycling balance of SSCs and preserving their osteogenic potential, while it was 384 found to be dispensable for their adipogenic and chondrogenic differentiation. Some other BM 385 cellular components contributed to the dysregulation of the bone phenotype. We observed in 386 trabecular area an increase in OCL number. However, the osteoclastogenic differentiation 387 potential of OCL precursors and the resorptive function of differentiated OCLs were not 388 affected *in vitro* by the Cxcr4¹⁰¹³ mutation. Therefore, the osteopenia might proceed from a 389 deregulated bone matrix resorption that might not be compensated enough by bone-forming 390 cells, enlightening further the strong entanglement between both actors of bone remodeling. 391 Unravelling the mechanisms leading to such an alteration of the skeletal landscape with a focus 392 on the defective osteogenic capacities of SSCs driving the observed excessive bone defect will 393 require further investigations using specific conditional mouse models. Importantly, defective 394 osteogenic capacities were also evidenced in vitro in BMSCs from WS patients. These 395 anomalies establish the C-tail of CXCR4 as an important regulatory domain of the receptor 396 function in BM stromal cell biology in both mice and humans. In light of previous works^{40,41,43,44}, our results also suggest that both increased and decreased Cxcr4-mediated 397

398 signaling negatively impact skeletal stromal elements, thus indicating that fine-tuning of Cxcr4 399 signaling is critical for maintenance and osteogenic specification of adult SSCs. Although the 400 underlying molecular mechanisms remain to be elucidated, Cxcr4 might act as a rheostat 401 regulating the strength and kinetic of signaling pathways involved in osteogenic fate 402 specification of SSCs. Interestingly, a recent work using a new mouse model of WS further 403 illustrated the crucial role of fine-tuned Cxcr4-mediated signaling in mesenchymal 404 stromal/stem cell (MSC) function⁴⁶. Indeed, the lymphopoiesis process was reduced, as 405 observed in our model⁵³, because of a dysregulated transcriptome in MSCs isolated from the 406 flushed marrow fraction and characterized by a switch from an adipogenic to an osteolineage-407 prone program with limited lymphopoietic activity. This might proceed from reduced 408 expression of IL-7 and excessive signaling through the lymphotoxin beta receptor in MSCs. 409 Whether these changes are observed in the BM of our mouse model and how they would 410 contribute to the bone loss warrant further investigations. Moreover, mice deficient for the gene 411 encoding the transcription factor Ebf3 display an opposite BM phenotype to the one of 412 $Cxcr4^{1013}$ -bearing mice, characterized by osteosclerosis with HSC depletion and reduced 413 expression of niche factors⁶⁹. This was related to the uncontrolled ability of *Ebf3*-deficient SSCs 414 to differentiate into OBLs. Further studies are required to address the status of Ebf3 and 415 downstream target genes that act to modulate osteogenic fate of SSCs in Cxcr4¹⁰¹³-bearing 416 mice. A potential crosstalk between distinct SSC subsets, either prone to differentiate into 417 osteochondro-lineage cells or perivascular and adipocyte lineage cells, has been reported⁷⁴. This 418 seems to imply ligand-receptor gene pairs such as TGFB, WNT or BMP ligands and their 419 cognate receptors that regulate SSC fate decision. Whether and how the Cxcl12/Cxcr4 signaling 420 axis contributes to these regulatory mechanisms across SSC types remains also to be explored. 421 We reported that loss of Cxcr4 signaling termination impairs overall number, impedes 422 cell cycle progression, and limits osteogenic differentiation of SSCs. Indeed, mutant mice have 423 a global alteration of the bone stromal landscape, including decreased numbers of SSCs and 424 their progeny including early and committed OPCs and impaired architecture of trabecular and 425 cortical bone microstructures that occurred in a mutated allele copy number-dependent manner. 426 Altogether, these findings indicate that the gain-of-Cxcr4-function mutation promotes a 427 reduced OBL commitment and differentiation, but does not alter the bone forming activity of 428 individual OBL. Congruent with this, chronic treatment with AMD3100 normalized in vitro the 429 osteogenic properties of mutant SSCs. Impaired Cxcr4 desensitization might alter the balance 430 between quiescence and differentiation of mutant SSCs and reduce the number of osteogenic-431 endowed precursors. Currently, the prevailing view is that BM Cxcl12-expressing stromal cells 432 display slow cell cycle progression and constitute an active source of trabecular and cortical 433 OBLs under physiological conditions, as well as in response to injury^{6,9,28,31,69}. We found a 434 higher proportion of quiescent SSCs in mutant mice that was particularly evident in 1013/1013 435 SSCs, thus suggesting the importance of Cxcr4 desensitization in controlling SSC proliferation 436 and quiescence and likely their capacity to give rise to osteogenic cells.

437 Loss of bone content in mutant mice was accompanied by a higher number of OCLs 438 within the trabecular bones, possibly reflecting that the Cxcr4 mutation was intrinsically 439 perturbing the OCL differentiation process. This seems not to be the case since we showed that 440 defective Cxcr4 desensitization did not increase in vitro differentiation of OCLs from mutant 441 BM progenitors, nor their mineral matrix resorbing capacities. BM chimeras leading to a WT 442 hematopoietic development into a mutant bone environment further ruled out the sole 443 involvement of an uncontrolled bone resorption due to defective OCLs with excessive activity. 444 These cells derive from monocytic lineage precursors upon stimulation by RankL and M-445 $Csf^{75,76}$. In a constant cross interaction between the bone forming and the bone resorbing 446 pathways, these osteoclastic cytokines are produced by mature and immature stromal cell 447 populations within the BM^{9,77,78}. While we did not observe increased Rank-L, M-Csf or Opg 448 (encoding a Rank-L antagonist) gene expression in sorted committed OPCs from mutant bones, 449 we cannot exclude that modification of the bone stroma due to osteogenic defects might in turn 450 modulate the production of osteoclastic factors from the mutant bone environment. Supporting 451 this assumption, co-cultures of WT OCL progenitors with *in vitro* expanded Cxcr4¹⁰¹³-bearing 452 bone-derived stromal cells, stimulated to produce osteoclastogenic factors, led to enhanced 453 osteoclastogenesis compared to WT stromal cells. No increase in Rank-L or M-Csf expression 454 nor decrease in *Opg* level could be detected, suggesting the involvement of other additional 455 mediators. It has recently been shown that intrinsic aging of SSCs resulted in higher proportion 456 of stromal lineages producing pro-inflammatory and pro-resorptive factors, promoting myeloid skewing, and osteoclastic activity³⁰. Whether a similar mechanism occurs in $Cxcr4^{1013}$ -bearing 457 458 mutant mice remains to be characterized. Moreover, BM chimeras leading to a mutant 459 hematopoietic development into a WT bone environment displayed dysregulated bone 460 landscape, thus emphasizing that transplanted hematopoietic cells can participate in bone loss 461 through direct and/or indirect actions on osteoclastogenesis. Despite altered hematopoiesis in such chimeric mice, the myeloid skewing reported elsewhere⁵³ might account for excessive 462 463 OCL number. As well, the reduced lymphopoiesis observed^{46,53} still led to generation of mature 464 B and T lymphocytes that are present in the BM and hence may act as potential actors in bone 465 erosion as they can produce osteoclastogenic mediators such as Rank-L in non-physiological 466 settings⁷⁹. Whether such action of mutant hematopoietic donor cells recreates a pro-467 osteoclastogenic environment through a remodeling of the myeloid and lymphoid 468 compartments deserves further investigations. Interestingly, the dysregulated bone landscape 469 in BM chimeras with a mutant hematopoietic compartment in WT recipients was even stronger 470 than that observed in mutant mice at steady-state. This observation raises the intriguing 471 possibility of a pro-osteogenic effect of one or several Cxcr4¹⁰¹³-bearing radioresistant cell 472 type(s). To test this possibility, further work will be required using mouse model where the473 mutation is carried in a cell-specific manner.

474 Osteogenesis is regulated, among different mechanisms, by undifferentiated skeletal 475 cells and more specified osteolineage cells that express factors promoting or preventing their own differentiation into OBLs^{23,59,69,80}. In BM, HSPC niches constitute critical spatio-temporal 476 477 regulatory units composed of multiple cell populations of hematopoietic and non-hematopoietic 478 origin cross-interacting with each other's in a dynamic setting^{1,3,9,81,82}. This implies that immune 479 and vascular cells among others may influence the osteogenic differentiation process⁸³. Again, in BM chimeras in which Cxcr4¹⁰¹³-bearing HSPCs were differentiating into a WT bone 480 481 environment, we reported a similar bone loss as observed in mutant mice, thus indicating cell-482 extrinsic Cxcr4-mediated regulation of the skeletal landscape. This also suggests that neither 483 the epiphyseal cartilage nor any developmental defect contribute to impaired trabecular bone 484 architecture in adult mutant mice, and further supports the notion that HSPCs, as osteolineage 485 cells do, express regulating osteogenic factors such as BMP-2, BMP-7 and WNT3a, that are 486 particularly involved in SSC osteogenesis specification¹⁷. Whether and how hematopoietic 487 cells, or other BM components such as vascular cells, participate in the defective osteolineage 488 specification of SSCs in *Cxcr4¹⁰¹³*-bearing mice deserves further investigations.

489 Finally, we reported that five out of nineteen patients with WS and carrying distinct 490 autosomal-dominant mutations in CXCR4 exhibit a decrease in BMD at different anatomical 491 sites. Although this would merit to be extended to a larger cohort before introducing any 492 potential bone-affecting drugs, these data suggest that accelerated osteopenia/osteoporosis and 493 increased risk of fractures may constitute a novel feature of WS. Lack of CXCR4 494 desensitization could be mechanistically involved in such anomaly since BMSCs from WS 495 patients carrying a heterozygous CXCR4 mutation displayed in vitro impaired capacities to 496 differentiate into osteogenic, but not adipogenic, cells. Strikingly, we observed that chondro-

497	and adipo-genic differentiation of murine mutant SSCs was normal both in situ and in vitro.
498	Considering recent studies unraveling human SSCs expressing the CXCL12/CXCR4 axis with
499	osteoblastogenic and, depending on their tissue origin, adipocytic potential ^{18,84} , our findings
500	pave the way for exploring the BM of WS patients in search for potential defect(s) in these
501	skeletal populations.
502	

504 **METHODS**

505 Healthy and WS donors and bone mineral density measurements

506 Investigations of human BM samples were performed in compliance with Good Clinical 507 Practices and the Declaration of Helsinki. The study was approved by the Ethical Board Ile-de-508 France X. Recruited WS patients were not compensated and gave their written informed 509 consent for participating to the clinical study that has been approved by NIAID Institutional 510 Review Board (IRB). Cryopreserved BM aspirates from two WS patient (NIH protocol 09-I-511 0200) were provided through a NIH Material Transfer Agreement. The samples were 512 anonymized. BM samples from seven healthy donors that were matched for age and sex and 513 used as control subjects were isolated from hip replacement surgery samples (Protocol 17-030, 514 n° ID-RCB: 2017-A01019-44). Primary BMSCs from healthy and WS donors were amplified 515 and used at passage 1 to 3. For BMD assessment, data were collected from nineteen WS patients 516 as part of an IRB approved clinical protocol conducted at the NIH (NIAID Protocol #2014-I-517 0185, IND # 118767). Patients had a baseline bone density scan as part of a drug treatment trial 518 (NCT02231879) comparing 1 year of twice daily filgrastim (Neupogen) versus plerixafor 519 (Mozobil) in a randomized, blinded crossover design. There were 13 women and 6 men with 520 an average age of 30.5 years (range 10-56). The samples were anonymized. Patients had been 521 on filgrastim (Neupogen) for an average of 5.7 years prior to enrolling in the trial (range 0-27). 522 6 of the 19 had not used filgrastim regularly prior to trial enrollment. BMD values expressed as 523 T- or Z-scores were measured by total body dual-energy X-ray absorptiometry with a Lunar 524 iDXA densitometer (GE Healthcare). Five WS patients had abnormal screening bone density 525 by WHO criteria, anonymized at the start of the Phase 3 trial (Table 1), while the other 14 526 patients had normal bone density.

527

528 Mice and genotyping

529 All mice were bred in our animal facility under a 12h light/dark cycle, specific pathogen-free 530 conditions (EOPS status) and fed *ad libitum*. For breeding, mice were in conventional cages 531 with filter top. For experimentation, mice were housed in individually ventilated cages. All 532 experiments were performed in accordance with the European Union guide for the care and use 533 of laboratory animals and have been reviewed and approved by institutional review committees 534 (CEEA-26, Animal Care and Use Committee, Villejuif, France and Comité d'Ethique Paris-535 Nord/N°121, Paris, France). Cxcr $4^{+/1013}$ (+/1013) mice were generated by a knock-in strategy⁵¹. Homozygous Cxcr4^{1013/1013}(1013/1013) mice were obtained by crossing heterozygous +/1013 536 537 mice. WT mice were used as controls. Unless specified, all mice were littermates, females and 538 age-matched (8-12 wk-old). Adult Boy/J (CD45.1) (Charles River) mice were used as BM 539 donors. Daily observation was performed to ensure that no animal was left in a state of pain or 540 suffering during experimentation. Euthanasia was performed by increasing gradient of CO₂.

541

542 Sample isolation in mice

543 Mouse SSCs were obtained from bones after centrifugation of intact femurs, tibias and hips to 544 flush out the BM cells. Flushed long bones were cut into fine pieces before enzymatic digestion 545 with 2.5 U/mL collagenase type I (Thermofisher) for 45 min at 37°C under agitation. Released 546 cells were filtered and washed with PBS, 2% FBS (Fetal Bovine Serum). Cell numbers were 547 standardized as total counts per two legs. Peripheral blood was collected by cardiac puncture. 548 Freshly isolated cells were either immunophenotyped, incubated at 37°C for 60 min in RPMI 549 20 mM HEPES 0.5% BSA (Euromedex) prior to chemokine receptor internalization studies, or 550 expanded in a MEM medium supplemented with 10% FBS, 1% P/S (penicillin 100 Units/mL, 551 streptomycin 100 Units/mL, Gibco) and 50 μM β-mercaptoethanol (PAN biotech). For BMD 552 quantification, lumbar spines were fixed overnight in ethanol 70° and analyzed by dual-energy

- X-ray absorptiometry with an ultrafocus DXA densitometer (Faxitron). Quantifications were
 made on a ROI of 2 lumbar spines.
- 555

556 Flow-cytometric analyses

557 Mouse and human staining analyses were carried out on an LSRII Fortessa flow cytometer (BD 558 Biosciences) using the antibodies (Abs) described in Table S1. A Live/Dead Fixable Aqua Dead 559 Cell Stain Kit (Biolegend) was used. To assess the compartmentalization of CXCR4 and 560 ACKR3, human BMSCs were incubated with saturating concentrations of non-conjugated 561 mouse anti-human CXCR4 or ACKR3 Abs, washed in PBS, fixed and permeabilized using the 562 BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences). BMSCs were 563 subsequently stained with anti-CXCR4 and -ACKR3 conjugated mAbs, or the corresponding 564 isotype control, at 4°C for 30 min and then analyzed by flow cytometry. FACS Diva software 565 version 7 (BD) were used for collecting data. FLOWJO v10.7 (BD) and GraphPad Prism v8.0e 566 (GraphPad software Inc.) were used for analyzing flow cytometric data.

567

568 In vitro functional assays

569 Mouse CFU-Fs were performed by plating 1×10^5 bone cells at passage 2-3 from WT and mutant 570 mice. Human CFU-Fs were performed by plating 0.2 x 10³ BMSCs into a 25 cm² flask at 571 passage 3 from healthy or WS donors. After 7 or 10 days of culture, colonies were fixed with 572 ethanol 70%, stained with 2% crystal violet (Sigma-Aldrich), and counted with a binocular 573 magnifying glass. For chemotaxis assays, $5x10^4$ SSCs were added to the upper chambers of a 574 24-well plate with 8-µm-pore-size Transwell inserts (EMD Millipore) containing or not 1 nM 575 Cxcl12 (R&D Systems) in the lower chamber. For inhibiting Cxcr4-mediated signaling, 10 µM 576 AMD3100 (Sigma-Aldrich) was added in the upper and lower chambers. After 24h, membranes 577 were removed and fixed in 4% paraformaldehyde (PFA). The cells that migrated to the lower

578 side of the membrane were stained with 0.1% crystal violet and three fields from each insert 579 were counted under a light microscope. Cxcr4 and Ackr3 internalization assays were performed 580 by incubating total bone cells at 37°C for 45 min with 10 nM Cxcl12. Then the reaction was 581 stopped by adding ice-cold RPMI and quick centrifugation at 4°C. After one wash in acidic 582 glycine buffer at pH= 4.3, levels of Cxcr4 and Ackr3 membrane expression were determined 583 by flow cytometry. Cxcr4 or Ackr3 expression was calculated as follows: (Cxcr4 or Ackr3 584 geometric MFI of treated cells/Cxcr4 or Ackr3 geometric MFI of unstimulated cells) \times 100; 585 100% corresponds to receptor expression at the surface of cells incubated in medium alone. For 586 the chemokine scavenging assay, cultured SSCs were harvested by trypsinization and placed in 587 complete medium for 90 min at 37°C and 5% CO₂ to normalize receptor expression. 4x10⁶ 588 cells/mL were pre-incubated with 100 µM CCX733, a functional Ackr3 antagonist or vehicle 589 in 1% BSA/PBS for 45 min at room temperature (RT). Then, $2x10^6$ cells/mL were incubated in 590 presence of 5 nM AF647-Cxcl12 (Almac) in 1% BSA/PBS during 45-60 min at 37°C to allow 591 internalization or on ice to inhibit this process. Cells were washed with 1% BSA/PBS and then 592 either treated with an acidic glycine wash buffer pH= 2.7 for 3 min to dissociate cell-surface-593 bound chemokine, or washed with PBS to estimate internalized plus cell-surface-bound control. 594 AF647 fluorescence (geometric MFI) was determined by flow cytometry. Phosphoflow assays 595 were performed with the PerFix EXPOSE kit (Beckman coulter) on cultured SSCs and an anti-596 phospho Erk (pT202/pY204) was used. Fold change was calculated as follows: (Phospho-Erk 597 geometric MFI of stimulated cells/Phospho-Erk geometric MFI of unstimulated cells).

598

599 In vivo functional assays

600 For BM transplantation experiments, 1.5×10^6 total marrow cells from young CD45.1⁺ WT mice

601 were injected i.v. into lethally irradiated (two rounds of 5.5 Gy separated by 3 h) young CD45.2⁺

602 WT, +/1013 or 1013/1013 recipient mice. For reverse experiments, 1.5x10⁶ total marrow cells

603	from CD45.2 ⁺ WT, +/1013 or 1013/1013 mice were injected into lethally irradiated CD45.1 ⁺
604	WT recipient mice. Chimerism was analyzed 3 or 16 weeks after transplantation. For Cxcr4
605	blockade experiments, mice were daily injected intraperitoneally with 5 mg/kg AMD3100 or
606	PBS during 3 weeks. BM were harvested 2 h after the last injection and analyzed by flow
607	cytometry and imaging.

608

609 ELISA

610 Supernatants of culture-expanded human BMSCs were analyzed using a standardized ELISA

611 for human Cxcl12 (Quantikine; R&D Systems).

612

613 Bone immunostaining and histomorphometry

614 Mouse bones were fixed in 4% PFA overnight followed by one-week decalcification in EDTA 615 (0.5 M) at pH 7.4 under agitation. Bones were incubated in PBS with 20% sucrose and 2% 616 polyvinylpyrrolidone (PVP) (Sigma) at 4°C overnight and then embedded in PBS with 20% 617 sucrose, 2% PVP and 8% gelatin (Sigma) before storage at -80°C. Sections of 30 µm-thick 618 were rehydrated in PBS 1X, incubated 20 min at RT in PBS with 0.3% triton X-100, saturated 619 in blocking solution (PBS with 5% BSA) and finally incubated with primary Abs (Table S2). 620 After washing, secondary Abs were incubated for 1h at RT with DAPI for nuclear staining and 621 mounting using Permafluor mounting medium (Thermofisher). Images were acquired using TCS SP8 confocal microscope and processed using Fiji software. For alcian blue and perilipin 622 623 A staining, fixed and decalcified femur bones were embedded in paraffin, sectioned (7 µm-624 thick) and deparaffinized with xylene. Staining of cartilage tissues was performed with a 1 % 625 alcian blue solution for 30 min. Images were acquired using a LEICA DM4000B microscope 626 equipped with a DFC425C camera and processed with the Leica Application Suite V3.8 627 software. For perilipin A staining, heat induced epitope retrieval was performed in citrate 628 sodium buffer solution. Sections were saturated for 1h in PBS 1% BSA at RT, washed in PBS 629 0.2% BSA and 0.1% Triton X-100, and incubated with anti-perilipin A Ab in PBS BSA 1% 630 overnight at 4°C. After washing, sections were incubated with TRITC-coupled rabbit anti-631 guinea pig Ab in PBS 1% BSA for 45 min and counterstained with DAPI. For Osx staining, 16 632 µm frozen sections were permeabilized in TBS-0.3% Triton X-100 for 10 min and blocked in 633 TBS-2.5% BSA-2.5% Donkey Serum for 1h at RT. Sections were incubated with anti-Osx Ab 634 (rabbit, Santa Cruz SC-22536R) in blocking solution overnight at 4°C. After washing with 635 TBS+0.025% Triton X-100, sections were incubated in donkey anti-rabbit secondary Ab 636 dylight 550 (SA5-10039, invitrogen) in blocking solution. After washing, sections were 637 incubated 15 min at RT in DAPI at 0.1µg/mL prior to mounting in GB-Mount (Diagomics). Image acquisitions were done using the ApoTome optical sectioning system (Zeiss) with an 638 639 inverted microscope (Zeiss Axio Observer Z1). Osx quantification was performed using the ICY software. For human BMSC immunofluorescence studies, cells were plated on coverslips 640 641 and fixed with 4% PFA in PBS. Fixed cells were permeabilized with Triton X 0.3% for 10 min, 642 blocked with PBS 5% BSA, 5% goat serum and incubated with unlabeled primary CXCL12 643 mAb overnight at 4°C followed by secondary AF633-coupled goat anti-mouse polyclonal Ab 644 (Invitrogen) and the nuclear dye Hoechst 33342. Images were obtained with a Plan-645 Apochromatic objective using the LSM800 confocal microscope (Carl Zeiss). Sections were acquired as serial z stacks (0.39 µm apart) and were subjected to three-dimensional 646 647 reconstruction (Zen 2.3 System).

Bone histomorphometry was performed in plastic samples, allowing the measurements of bone formation and resorption parameters. Mouse femurs were fixed in ethanol 70°, dehydrated and embedded in methyl methacrylate resin. Five micrometer-thick coronal sections were cut parallel to the long axis of the femur using an SM2500S microtome (Leica, Germany). Sections were deplastified, rehydrated and stained with toluidine blue or with naphthol 3653 hydroxy-2-naphthoic acid 4-chloro-2-methylanilide (ASTR phosphate, Sigma, St Louis, 654 France) for detecting mature osteoclasts with TRAP staining. Quantifications were made on a 655 polarizing microscope (Nikon) using a software package (Bonolab) developed for bone 656 histomorphometry (Microvision, France). To allow the measure of dynamic parameters of bone 657 formation, mice were intraperitoneally injected with tetracycline (20 mg/kg) and calcein 658 (10 mg/kg; Sigma) 5 days and 1 day respectively before being killed. Two 12-um-thick 659 unstained sections were taken for measurement of the dynamic parameters under UV light. The 660 matrix apposition rate (MAR) was measured using the Microvision image analyzer by a 661 semiautomatic method using tetracycline and calcein double-labeled bone surfaces. The 662 mineralizing surfaces (MS/BS) were measured in the same areas using the objective eyepiece 663 Leitz integrate plate II. When specified, the cortical thickness was measured in paraffin-664 embedded sections stained with Toluidine Blue. The 2 cortices were measured using 665 histomorphometry software and expressed as mean of both cortices for each sample. All the 666 histomorphometric parameters were recorded in compliance with the recommendation of the 667 American Society for Bone and Mineral Research Histomorphometry Nomenclature 668 Committee. Five to six animals per genotype were analyzed by two different investigators.

669

670 Bone structure analysis by micro-computed tomography

Femurs were collected for bone microarchitecture analysis after fixation and before decalcification. They were analyzed with high-resolution microcomputed tomography (micro-CT) using a Skyscan 1272 microCT (SkyScan, Kontich, Belgium). Measurements were made on the femurs using the following acquisition parameters: voltage 60kV, pixel size 6 μ m, Filter Alu + 0.5mm. After 3-dimensional images reconstruction with NRecon[®], analyses were performed on the trabecular and cortical region (1.72 mm and 0.43 mm thickness, respectively). Morphometric parameters such as Bone Volume/Tissue volume (BV/TV, %), Trabecular number (Tb.Nb, 1/mm), Trabecular Separation (Tb.Sp, mm), Cortical Bone Volume (Ct.BV,

- 679 mm³) and Cortical Thickness (Ct.Th, mm) were assessed.
- 680

681 Cell culture and differentiation

682 Mouse osteoblastic differentiation was performed for 3 weeks in α -MEM medium with 10% 683 FBS, 1% P/S, 50 μ M β -mercaptoethanol supplemented with 50 μ g/mL L-ascorbic acid and 10 684 mM glycerophosphate (Sigma) either from SSCs or sorted OPCs. Alkaline phosphatase staining 685 was performed after 14 days of differentiation according to the Alkaline phosphatase Kit 686 (Sigma). At day 21, cultures were fixed with 4% PFA, stained with alizarin red and quantified 687 using the Osteogenesis assay kit (Millipore). When specified, AMD3100 (versus vehicle) was 688 added into the osteogenic medium every 2 days at 10 µM respectively. Chondro- and adipo-689 genic differentiations of SSCs were performed according to the StemPro-Chondrogenesis or -690 Adipogenic Differentiation Kits (ThermoFisher) for 2 weeks. After fixation, cells were treated 691 with either Alcian Blue 1% (Sigma) to stain chondrocyte matrix or Oil Red O solution (Sigma) 692 to reveal lipid droplets. For in vitro human osteogenic differentiation assays, expanded BMSCs 693 were seeded at 3 x 10^3 per cm² in α -MEM supplemented with 10% FBS and 1% antibiotics. 694 After cell adhesion, medium was replaced by α -MEM supplemented with 10% FBS, 1% 695 antibiotics and 0.1 μ M dexamethasone, 0.05 mM L-ascorbic acid-2-phosphate and 10 mM β -696 glycerophosphate. Medium was changed every 2 days during 3 weeks. Quantification of 697 mineralization was performed after Alizarin Red S staining⁸⁵. Human adipogenic 698 differentiation assays were performed as described for the murine ones.

699

700 Osteoclast differentiation and functional analysis

OCLs were differentiated *in vitro*⁸⁶. Briefly, 2.3 x 10⁵ BM cells/cm² were plated in MEM-alpha
(ThermoFisher) complemented with 5% serum (Hyclone, GE Healthcare), 1% P/S, 50 μM 2-

mercaptoethanol, 25 ng/ml M-Csf and 30 ng/ml Rank-L (R&D Systems). OCL differentiation (multinucleated TRAP⁺ cells) was quantified at day 5 after TRAP coloration using the leukocyte acid phosphatase kit (Sigma). Matrix dissolution activity was evaluated by seeding a total of $2x10^4$ differentiated OCLs on 96-well osteoassay plates (Corning) in α -MEM containing 10% FBS and 30 ng/ml Rank-L. After 3 days, medium was removed and cells were detached by the addition of water. Resorbed areas were quantified using Fiji/ImageJ software⁸⁷.

710 **Co-culture assays between osteogenic cells and osteoclast precursors**

711 Mouse osteogenic cells were isolated from the bone fraction of WT or mutant mice as indicated 712 above. They were expanded in α -MEM medium with 10% FBS, 1% P/S, 50 μ M β -713 mercaptoethanol for 2 weeks, passaged and plated in 96-well plates (2 x 10⁴ cells/well). 714 Osteoclast precursors were obtained from CD11b⁺-enriched cells (with CD11b-Microbeads, 715 Milteniy Biotec, France) from the flushed marrow fraction of WT mice as previously described⁸⁶. They were added, in co-culture, to WT or mutant expanded osteogenic cells (5 x 716 717 10⁴ cell/well) and stimulated with 1,25-dihydroxy vitamin D3 (vitD3, 10 nM), prostaglandin 718 E2 (PGE2, 1 µM) and Dexamethasone (Dex, 50 nM) as previously described⁶⁵ in order to 719 stimulate osteogenic cells to produce RankL/MCSF and to inhibit OPG production^{88,89}. OCL 720 differentiation (multinucleated TRAP⁺ cells) was quantified at day 8 after TRAP coloration as 721 indicated above.

722

723 Cell cycle, viability, survival and proliferation assays

For flow cytometry-based cell cycle analyses, bone cells were permeabilized, fixed with the FOXP3 permeabilization kit (Foxp3/Transcription Factor Staining Buffer Set; eBioscience) and labelled with a Ki67 Ab and DAPI. For BrdU assays, mice were injected intraperitoneally with 180 µg BrdU (Sigma) and maintained with drinking water containing 800 µg/ml BrdU and 1%

728 glucose over 12 days. The BrdU labelling was analyzed by flow cytometry using the BrdU-729 FITC labeling kit (BD Biosciences). For in vitro BrdU incorporation, 3 µg/ml of BrdU was 730 added to the culture and after five days the percentage of incorporation was determined as 731 above. Apoptosis was measured using the Annexin V detection kit (BD Biosciences) with DAPI 732 staining. For *in vitro* proliferation assays, SSCs were detached with 0.5% trypsin and loaded at 733 3 x 10⁴ cells/well with cell trace violet (CTV, Thermofisher) for 15 min at 37°C. CTV dilution 734 was assessed by flow cytometry. To estimate the doubling time values, SSCs were seeded at 735 $3x10^3$ cells/cm² and counted after 3 days of culture. The doubling time was calculated as 736 follows: (time of culture $x \log(2))/(\log(\text{final number of SSC})-\log(\text{initial number of SSC}))$.

737

738 Quantitative real time-PCR

739 For mouse gene expression, total RNA was isolated from cultured or sorted SSCs and OPCs 740 using the RNeasy Plus Mini or Micro Kit (Qiagen) and reverse transcribed with oligo(dT) and 741 SuperScript II Reverse Transcriptase (Invitrogen). Quantitative RT-PCR reactions were 742 performed on a Light Cycler instrument (LC480, Roche Diagnostics) with the LightCycler 480 743 SYBR Green detection kit (Roche Diagnostics) using primers reported in Table S3. For human 744 gene expression, total RNA was isolated from cultured BMSCs using Trizol Reagent 745 (ThermoFisher). Reverse transcription was performed using SuperScriptVilo IV 746 (ThermoFisher). When required, total RNA from WS BMSCs and their related controls were 747 extracted from 0.2 x 10³ BMSCs and pre-amplified using CellsDirect One-Step qRT-PCR kit 748 (Invitrogen). PCR reactions were performed using primers reported in Table S3 with Power 749 SYBRGreen (Applied Biosystems) on a 7500 FAST apparatus (Applied Biosystems). Mouse 750 β -actin and 36b4 and human β -ACTIN and GAPDH were used as standards for normalization. 751 Relative quantification was determined by the comparative delta-Ct ($2^{-\Delta CT}$) method (fold changes calculated relative to house-keeping genes) or delta-delta-Ct $(2^{-\Delta\Delta CT})$ method (fold changes calculated by setting the mean values obtained from WT cells as one).

754

755 Multiplex qPCR

756 Multiplex qPCR was performed using the microfluidic Biomark system. One hundred SSCs 757 were sorted into PCR tubes containing 5 μ l of reverse transcription/pre-amplification mix 758 containing 2X reaction buffer, SuperScriptIII from the CellsDirect One-Step qRT-PCR kit and 759 0.2X Taqman assay (Life technologies) (Table S4). cDNA pre-amplification was performed 760 during 22 cycles and pre-amplified product was diluted 1:5 in TE buffer before processing with 761 Dynamic Array protocol (Fluidigm). Cells expressing β -actin and control genes (Runx2, Coll α , 762 Alp and Ibsp) and not Pax5 and/or Cd3 (negative controls) were considered for analyses. 763 Expression of β -actin was used for normalization. Heatmaps were generated with http://www.heatmapper.ca using Z scores. 764

765

766 **RNA sequencing**

767 Pools of 3 x 10^3 SSCs or OPCs were sorted from the bone fraction into RLT buffer (Qiagen) 768 with 1% of β -mercaptoethanol. RNA was isolated using RNeasy Micro Kit. cDNAs were 769 generated from 400 to 1,000 pg of total RNA using Clontech SMART-Seq v4 Ultra Low Input 770 RNA kit for Sequencing (Takara Bio Europe) and amplified with 12 cycles of PCR by Seq-771 Amp polymerase. For Tn5 transposon tagmentation, 600 pg of pre-amplified cDNAs were used 772 by the Nextera XT DNA Library Preparation Kit (96 samples) (Illumina) followed by library 773 amplification of 12 cycles. Purification was performed with Agencourt AMPure XP and 774 SPRIselect beads (Beckman-Coulter). Sequencing reads were generated, in Paired-End mode, 775 on the GenomEast platform (Illumina). FastQC program was used to evaluate the quality of the 776 raw sequencing data and reads shorter than 50 bp were removed. Reads were aligned to the Mus *musculus* genome (mm10 build) using the Star tool⁹⁰. Gene expression quantification was obtained using read counting software $Htseq^{91}$. Normalization and differential analysis were carried out with DESeq2 package by applying the Benjamini-Hochberg FDR correction (p < 0.05; 1.5-fold) for comparison between samples. Heatmaps and volcano plots were obtained using the web server Heatmapper and EnhancedVolcano packages respectively.

782

783 Statistics

784 All statistical analyses were conducted using Prism software (GraphPad Software). A Kruskal-

785 Wallis test was used to determine the significance of the difference between means of WT,

+/1013 and 1013/1013 groups. Unless specified, the unpaired two-tailed Student *t* test was used

787 to compare means among two groups.

788

789 DATA AVAILABILITY

790 RNA-seq data that support the findings of this study have been deposited in the Gene 791 Expression Omnibus repository with the accession code GSE217422 792 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217422). The data that support the 793 findings of this study are available from the corresponding author upon request. Source data 794 are provided with this paper.

796 **REFERENCES**

- 1. Wei, Q. & Frenette, P. S. Niches for Hematopoietic Stem Cells and Their Progeny. *Immunity*48, 632-648 (2018). https://doi.org:10.1016/j.immuni.2018.03.024
- 799 2. Bianco, P. Stem cells and bone: a historical perspective. *Bone* 70, 2-9 (2015).
 800 https://doi.org:10.1016/j.bone.2014.08.011
- 3. Baryawno, N. et al. A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and
- 802
 Leukemia.
 Cell
 177,
 1915-1932
 e1916
 (2019).

 803
 https://doi.org:10.1016/j.cell.2019.04.040
- 4. Grassinger, J., Haylock, D. N., Williams, B., Olsen, G. H. & Nilsson, S. K. Phenotypically
 identical hemopoietic stem cells isolated from different regions of bone marrow have
 different biologic potential. *Blood* 116, 3185-3196 (2010).
 https://doi.org:10.1182/blood-2009-12-260703
- 5. Kiel, M. J. et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells
- and reveal endothelial niches for stem cells. *Cell* 121, 1109-1121 (2005).
 https://doi.org:10.1016/j.cell.2005.05.026
- 811 6. Nakahara, F. *et al.* Engineering a haematopoietic stem cell niche by revitalizing
 812 mesenchymal stromal cells. *Nat Cell Biol* 21, 560-567 (2019).
 813 https://doi.org:10.1038/s41556-019-0308-3
- 814 7. Pinho, S. et al. Lineage-Biased Hematopoietic Stem Cells Are Regulated by Distinct Niches.
- 815 Dev Cell 44, 634-641 e634 (2018). <u>https://doi.org:10.1016/j.devcel.2018.01.016</u>
- 816 8. Sun, J. *et al.* Clonal dynamics of native haematopoiesis. *Nature* 514, 322-327 (2014).
 817 https://doi.org:10.1038/nature13824
- 818 9. Tikhonova, A. N. *et al.* The bone marrow microenvironment at single-cell resolution. *Nature*
- 819 **569**, 222-228 (2019). <u>https://doi.org:10.1038/s41586-019-1104-8</u>

- 10. Acar, M. *et al.* Deep imaging of bone marrow shows non-dividing stem cells are mainly
 perisinusoidal. *Nature* 526, 126-130 (2015). https://doi.org:10.1038/nature15250
- 11. Asada, N., Takeishi, S. & Frenette, P. S. Complexity of bone marrow hematopoietic stem
 cell niche. *Int J Hematol* 106, 45-54 (2017). https://doi.org:10.1007/s12185-017-2262-
- 824

- Balzano, M. *et al.* Nidogen-1 Contributes to the Interaction Network Involved in Pro-B Cell
 Retention in the Peri-sinusoidal Hematopoietic Stem Cell Niche. *Cell Rep* 26, 32573271 e3258 (2019). https://doi.org:10.1016/j.celrep.2019.02.065
- 828 13. Comazzetto, S. et al. Restricted Hematopoietic Progenitors and Erythropoiesis Require SCF
- from Leptin Receptor+ Niche Cells in the Bone Marrow. *Cell Stem Cell* **24**, 477-486
- 830 e476 (2019). <u>https://doi.org:10.1016/j.stem.2018.11.022</u>
- 14. Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular
 cells maintain haematopoietic stem cells. *Nature* 481, 457-462 (2012).
- 833 <u>https://doi.org:10.1038/nature10783</u>
- 834 15. Kunisaki, Y. *et al.* Arteriolar niches maintain haematopoietic stem cell quiescence. *Nature*
- 835 **502**, 637-643 (2013). <u>https://doi.org:10.1038/nature12612</u>
- 836 16. Zhong, L. et al. Single cell transcriptomics identifies a unique adipose lineage cell
- 837 population that regulates bone marrow environment. *Elife* **9** (2020).
- 838 <u>https://doi.org:10.7554/eLife.54695</u>
- 839 17. Chan, C. K. et al. Identification and specification of the mouse skeletal stem cell. Cell 160,
- 840 285-298 (2015). <u>https://doi.org:10.1016/j.cell.2014.12.002</u>
- 18. Chan, C. K. F. et al. Identification of the Human Skeletal Stem Cell. Cell 175, 43-56 e21
- 842 (2018). <u>https://doi.org:10.1016/j.cell.2018.07.029</u>

- 19. Worthley, D. L. et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and
- 844 reticular stromal potential. *Cell* 160, 269-284 (2015).
 845 https://doi.org:10.1016/j.cell.2014.11.042
- 20. Calvi, L. M. *et al.* Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature*425, 841-846 (2003).
- 848 21. Greenbaum, A. *et al.* CXCL12 in early mesenchymal progenitors is required for
 849 haematopoietic stem-cell maintenance. *Nature* 495, 227-230 (2013).
 850 https://doi.org:10.1038/nature11926
- 22. Jung, Y. *et al.* Hematopoietic stem cells regulate mesenchymal stromal cell induction into
 osteoblasts thereby participating in the formation of the stem cell niche. *Stem Cells* 26,

853 2042-2051 (2008). <u>https://doi.org:10.1634/stemcells.2008-0149</u>

- 854 23. Mendez-Ferrer, S. *et al.* Mesenchymal and haematopoietic stem cells form a unique bone
 855 marrow niche. *Nature* 466, 829-834 (2010). <u>https://doi.org:10.1038/nature09262</u>
- 856 24. Nakamura, Y. et al. Isolation and characterization of endosteal niche cell populations that
- 857 regulate hematopoietic stem cells. *Blood* **116**, 1422-1432 (2010).
- 858 <u>https://doi.org:10.1182/blood-2009-08-239194</u>
- 859 25. Omatsu, Y. *et al.* The essential functions of adipo-osteogenic progenitors as the
 860 hematopoietic stem and progenitor cell niche. *Immunity* 33, 387-399 (2010).
- 861 https://doi.org:10.1016/j.immuni.2010.08.017
- 26. Yoshihara, H. *et al.* Thrombopoietin/MPL signaling regulates hematopoietic stem cell
 quiescence and interaction with the osteoblastic niche. *Cell Stem Cell* 1, 685-697 (2007).
- 864 https://doi.org:10.1016/j.stem.2007.10.020
- 27. Zhang, J. *et al.* Identification of the haematopoietic stem cell niche and control of the niche
 size. *Nature* 425, 836-841 (2003).

- 867 28. Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G. & Morrison, S. J. Leptin-receptor-868 expressing mesenchymal stromal cells represent the main source of bone formed by 869 adult bone marrow. Cell Stem Cell 15, 154-168 (2014). 870 https://doi.org:10.1016/j.stem.2014.06.008
- 29. Wolock, S. L. *et al.* Mapping Distinct Bone Marrow Niche Populations and Their
 Differentiation Paths. *Cell Rep* 28, 302-311 e305 (2019).
 https://doi.org:10.1016/j.celrep.2019.06.031
- 874 30. Ambrosi, T. H. *et al.* Aged skeletal stem cells generate an inflammatory degenerative niche.

875 *Nature* **597**, 256-262 (2021). <u>https://doi.org:10.1038/s41586-021-03795-7</u>

- 31. Jeffery, E. C., Mann, T. L. A., Pool, J. A., Zhao, Z. & Morrison, S. J. Bone marrow and
 periosteal skeletal stem/progenitor cells make distinct contributions to bone
 maintenance and repair. *Cell Stem Cell* (2022).
 <u>https://doi.org:10.1016/j.stem.2022.10.002</u>
- 32. Ara, T. *et al.* Long-term hematopoietic stem cells require stromal cell-derived factor-1 for
 colonizing bone marrow during ontogeny. *Immunity* 19, 257-267 (2003).
- 882 <u>https://doi.org:10.1016/s1074-7613(03)00201-2</u>
- 33. Cordeiro Gomes, A. et al. Hematopoietic Stem Cell Niches Produce Lineage-Instructive
- 884 Signals to Control Multipotent Progenitor Differentiation. *Immunity* **45**, 1219-1231
- 885 (2016). <u>https://doi.org:10.1016/j.immuni.2016.11.004</u>
- 34. Itkin, T. *et al.* Distinct bone marrow blood vessels differentially regulate haematopoiesis.
 Nature 532, 323-328 (2016). <u>https://doi.org:10.1038/nature17624</u>
- 35. Nie, Y., Han, Y. C. & Zou, Y. R. CXCR4 is required for the quiescence of primitive
 hematopoietic cells. *J Exp Med* 205, 777-783 (2008).
 https://doi.org:10.1084/jem.20072513

- 36. Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic
 stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell
 niches. *Immunity* 25, 977-988 (2006).
- 894 37. Miao, R. *et al.* Competition between hematopoietic stem and progenitor cells controls
 895 hematopoietic stem cell compartment size. *Nat Commun* 13, 4611 (2022).
 896 https://doi.org:10.1038/s41467-022-32228-w
- 897 38. Ding, L. & Morrison, S. J. Haematopoietic stem cells and early lymphoid progenitors
 898 occupy distinct bone marrow niches. *Nature* 495, 231-235 (2013).
 899 https://doi.org:10.1038/nature11885
- 39. Agarwal, P. *et al.* Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence
 of Treatment-Resistant Leukemia Stem Cells. *Cell Stem Cell* 24, 769-784 e766 (2019).
- 902 <u>https://doi.org:10.1016/j.stem.2019.02.018</u>
- 40. Hosogane, N. *et al.* Stromal derived factor-1 regulates bone morphogenetic protein 2induced osteogenic differentiation of primary mesenchymal stem cells. *Int J Biochem*
- 905 *Cell Biol* **42**, 1132-1141 (2010). https://doi.org:10.1016/j.biocel.2010.03.020
- 906 41. Li, G. et al. Hypermethylation of microRNA-149 activates SDF-1/CXCR4 to promote
- 907 osteogenic differentiation of mesenchymal stem cells. *J Cell Physiol* **234**, 23485-23494
- 908 (2019). <u>https://doi.org:10.1002/jcp.28917</u>
- 42. Shahnazari, M., Chu, V., Wronski, T. J., Nissenson, R. A. & Halloran, B. P.
 CXCL12/CXCR4 signaling in the osteoblast regulates the mesenchymal stem cell and
 osteoclast lineage populations. *FASEB J* 27, 3505-3513 (2013).
 https://doi.org:10.1096/fj.12-225763
- 43. Tzeng, Y. S. *et al.* Imbalanced Osteogenesis and Adipogenesis in Mice Deficient in the
 Chemokine Cxcl12/Sdf1 in the Bone Mesenchymal Stem/Progenitor Cells. *J Bone Miner Res* 33, 679-690 (2018). https://doi.org:10.1002/jbmr.3340

- 916 44. Zhu, W., Liang, G., Huang, Z., Doty, S. B. & Boskey, A. L. Conditional inactivation of the
- 917 CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to impaired
- 918
 osteoblast
 development.
 J
 Biol
 Chem
 286,
 26794-26805
 (2011).

 919
 https://doi.org:10.1074/jbc.M111.250985
- 45. Matsushita, Y. *et al.* A Wnt-mediated transformation of the bone marrow stromal cell
 identity orchestrates skeletal regeneration. *Nat Commun* 11, 332 (2020).
 https://doi.org:10.1038/s41467-019-14029-w
- 923 46. Zehentmeier, S. et al. Dysregulated stem cell niches and altered lymphocyte recirculation
- 224 cause B and T cell lymphopenia in WHIM syndrome. *Sci Immunol* **7**, eabo3170 (2022).
- 925 <u>https://doi.org:10.1126/sciimmunol.abo3170</u>
- 47. Dotta, L., Tassone, L. & Badolato, R. Clinical and genetic features of Warts,
 Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome. *Curr Mol Med* 11, 317-325 (2011).
- 48. Kawai, T. & Malech, H. L. WHIM syndrome: congenital immune deficiency disease. *Curr Opin Hematol* 16, 20-26 (2009). https://doi.org:10.1097/MOH.0b013e32831ac557
- 49. Murphy, P. M. & Heusinkveld, L. Multisystem multitasking by CXCL12 and its receptors
- 932
 CXCR4
 and
 ACKR3.
 Cytokine
 109,
 2-10
 (2018).

 933
 https://doi.org:10.1016/j.cvto.2017.12.022
- 50. Hernandez, P. A. *et al.* Mutations in the chemokine receptor gene CXCR4 are associated
 with WHIM syndrome, a combined immunodeficiency disease. *Nat Genet* 34, 70-74
 (2003). <u>https://doi.org:10.1038/ng1149</u>
- 937 51. Balabanian, K. *et al.* Proper desensitization of CXCR4 is required for lymphocyte
 938 development and peripheral compartmentalization in mice. *Blood* 119, 5722-5730
 939 (2012). https://doi.org:10.1182/blood-2012-01-403378

- 940 52. Biajoux, V. et al. Efficient Plasma Cell Differentiation and Trafficking Require Cxcr4
- 941
 Desensitization.
 Cell
 Rep
 17,
 193-205
 (2016).

 942
 https://doi.org:10.1016/j.celrep.2016.08.068
- 943 53. Freitas, C. et al. Lymphoid differentiation of hematopoietic stem cells requires efficient
- 944 Cxcr4 desensitization. J Exp Med 214, 2023-2040 (2017).
 945 https://doi.org:10.1084/jem.20160806
- 946 54. Alouche, N. et al. Hematologic disorder-associated Cxcr4 gain-of-function mutation leads
- 947 to uncontrolled extrafollicular immune response. *Blood* **137**, 3050-3063 (2021).
- 948 <u>https://doi.org:10.1182/blood.2020007450</u>
- 949 55. Haribabu, B. et al. Regulation of human chemokine receptors CXCR4. Role of
- phosphorylation in desensitization and internalization. *J Biol Chem* **272**, 28726-28731
- 951 (1997). <u>https://doi.org:10.1074/jbc.272.45.28726</u>
- 952 56. Balabanian, K. et al. WHIM syndromes with different genetic anomalies are accounted for
- by impaired CXCR4 desensitization to CXCL12. *Blood* 105, 2449-2457 (2005).
 https://doi.org:10.1182/blood-2004-06-2289
- 955 57. Mayol, K., Biajoux, V., Marvel, J., Balabanian, K. & Walzer, T. Sequential desensitization
- 956 of CXCR4 and S1P5 controls natural killer cell trafficking. *Blood* **118**, 4863-4871
- 957 (2011). <u>https://doi.org:10.1182/blood-2011-06-362574</u>
- 958 58. Matsushita, Y., Ono, W. & Ono, N. Flow Cytometry-Based Analysis of the Mouse Bone
- 959 Marrow Stromal and Perivascular Compartment. *Methods Mol Biol* **2308**, 83-94 (2021).
- 960 <u>https://doi.org:10.1007/978-1-0716-1425-9_7</u>
- 961 59. Mende, N. *et al.* Prospective isolation of nonhematopoietic cells of the niche and their
- 962 differential molecular interactions with HSCs. *Blood* **134**, 1214-1226 (2019).
- 963 <u>https://doi.org:10.1182/blood.2019000176</u>

- 60. Morikawa, S. *et al.* Prospective identification, isolation, and systemic transplantation of
 multipotent mesenchymal stem cells in murine bone marrow. *J Exp Med* 206, 24832496 (2009). https://doi.org:10.1084/jem.20091046
- 967 61. Parfitt, A. M. Osteoclast precursors as leukocytes: importance of the area code. *Bone* 23,
- 968 491-494 (1998). <u>https://doi.org:10.1016/s8756-3282(98)00140-9</u>
- 969 62. Zhu, H. *et al.* A protocol for isolation and culture of mesenchymal stem cells from mouse
- 970 compact bone. *Nat Protoc* **5**, 550-560 (2010). <u>https://doi.org:10.1038/nprot.2009.238</u>
- 63. Abou Nader, Z., Espeli, M., Balabanian, K. & Lemos, J. P. Culture, Expansion and
 Differentiation of Mouse Bone-Derived Mesenchymal Stromal Cells. *Methods Mol Biol*
- 973 **2308**, 35-46 (2021). <u>https://doi.org:10.1007/978-1-0716-1425-9_3</u>
- 64. Wright, H. L., McCarthy, H. S., Middleton, J. & Marshall, M. J. RANK, RANKL and
 osteoprotegerin in bone biology and disease. *Curr Rev Musculoskelet Med* 2, 56-64
- 976 (2009). <u>https://doi.org:10.1007/s12178-009-9046-7</u>
- 65. Ciucci, T. *et al.* Bone marrow Th17 TNFalpha cells induce osteoclast differentiation, and
 link bone destruction to IBD. *Gut* 64, 1072-1081 (2015). <u>https://doi.org:10.1136/gutjnl-</u>
 2014-306947
- 980 66. Feng, X. & McDonald, J. M. Disorders of bone remodeling. Annu Rev Pathol 6, 121-145
- 981 (2011). <u>https://doi.org:10.1146/annurev-pathol-011110-130203</u>
- 67. Sims, N. A. & Martin, T. J. Osteoclasts Provide Coupling Signals to Osteoblast Lineage
 Cells Through Multiple Mechanisms. *Annu Rev Physiol* 82, 507-529 (2020).
- 984 <u>https://doi.org:10.1146/annurev-physiol-021119-034425</u>
- 985 68. Signer, R. A. & Morrison, S. J. Mechanisms that regulate stem cell aging and life span. *Cell*
- 986 Stem Cell **12**, 152-165 (2013). <u>https://doi.org:10.1016/j.stem.2013.01.001</u>

- 69. Seike, M., Omatsu, Y., Watanabe, H., Kondoh, G. & Nagasawa, T. Stem cell niche-specific
 Ebf3 maintains the bone marrow cavity. *Genes Dev* 32, 359-372 (2018).
 https://doi.org:10.1101/gad.311068.117
- 990 70. Mizoguchi, T. *et al.* Osterix marks distinct waves of primitive and definitive stromal
 991 progenitors during bone marrow development. *Dev Cell* 29, 340-349 (2014).
- 992 <u>https://doi.org:10.1016/j.devcel.2014.03.013</u>
- 993 71. Maes, C. *et al.* Osteoblast precursors, but not mature osteoblasts, move into developing and
- 994 fractured bones along with invading blood vessels. *Dev Cell* **19**, 329-344 (2010).
- 995 <u>https://doi.org:10.1016/j.devcel.2010.07.010</u>
- 996 72. Shen, B. et al. A mechanosensitive peri-arteriolar niche for osteogenesis and lymphopoiesis.
- 997 *Nature* **591**, 438-444 (2021). <u>https://doi.org:10.1038/s41586-021-03298-5</u>
- 998 73. Devignes, C. S. *et al.* HIF signaling in osteoblast-lineage cells promotes systemic breast
 999 cancer growth and metastasis in mice. *Proc Natl Acad Sci U S A* 115, E992-E1001
- 1000 (2018). <u>https://doi.org:10.1073/pnas.1718009115</u>
- 1001 74. Ambrosi, T. H. *et al.* Distinct skeletal stem cell types orchestrate long bone skeletogenesis.
- 1002 *Elife* **10** (2021). <u>https://doi.org:10.7554/eLife.66063</u>
- 1003 75. Cenci, S., Weitzmann, M. N., Gentile, M. A., Aisa, M. C. & Pacifici, R. M-CSF
- neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J Clin
 Invest 105, 1279-1287 (2000). https://doi.org:10.1172/JCI8672
- 1006 76. Cenci, S. *et al.* Estrogen deficiency induces bone loss by enhancing T-cell production of
- 1007 TNF-alpha. J Clin Invest 106, 1229-1237 (2000). <u>https://doi.org:10.1172/JCI11066</u>
- 1008 77. Cao, J. J. et al. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and
- alters the osteoclast precursor pool in the mouse. J Bone Miner Res 20, 1659-1668
- 1010 (2005). https://doi.org:10.1359/JBMR.050503

- 1011 78. Nakashima, T. *et al.* Evidence for osteocyte regulation of bone homeostasis through
 1012 RANKL expression. *Nat Med* 17, 1231-1234 (2011). <u>https://doi.org:10.1038/nm.2452</u>
- 1013 79. Wakkach, A., Rouleau, M. & Blin-Wakkach, C. Osteoimmune Interactions in Inflammatory
- 1014Bowel Disease: Central Role of Bone Marrow Th17 TNFalpha Cells in1015Osteoclastogenesis.FrontImmunol6,640(2015).
- 1016 <u>https://doi.org:10.3389/fimmu.2015.00640</u>
- 1017 80. Komori, T. Regulation of osteoblast differentiation by transcription factors. *J Cell Biochem*1018 **99**, 1233-1239 (2006). https://doi.org:10.1002/jcb.20958
- 1019 81. Aurrand-Lions, M. & Mancini, S. J. C. Murine Bone Marrow Niches from Hematopoietic
 1020 Stem Cells to B Cells. *Int J Mol Sci* 19 (2018). https://doi.org:10.3390/ijms19082353
- 1021 82. Bonaud, A., Lemos, J. P., Espeli, M. & Balabanian, K. Hematopoietic Multipotent
- 1022Progenitors and Plasma Cells: Neighbors or Roommates in the Mouse Bone Marrow1023Ecosystem?FrontImmunol12,658535(2021).
- 1024 <u>https://doi.org:10.3389/fimmu.2021.658535</u>
- 1025 83. Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and
 1026 osteogenesis by a specific vessel subtype in bone. *Nature* 507, 323-328 (2014).
- 1027 <u>https://doi.org:10.1038/nature13145</u>
- 1028 84. Xu, J. et al. Comparison of skeletal and soft tissue pericytes identifies CXCR4(+) bone
- 1029
 forming mural cells in human tissues. Bone Res 8, 22 (2020).

 1030
 https://doi.org:10.1038/s41413-020-0097-0
- 1031 85. Bisio, V., Espeli, M., Balabanian, K. & Anginot, A. Culture, Expansion and Differentiation
- 1032 of Human Bone Marrow Stromal Cells. *Methods Mol Biol* 2308, 3-20 (2021).
- 1033 <u>https://doi.org:10.1007/978-1-0716-1425-9_1</u>

- 1034 86. Ibanez, L. et al. Inflammatory Osteoclasts Prime TNFalpha-Producing CD4(+) T Cells and
- 1035
 Express
 CX3
 CR1.
 J
 Bone
 Miner
 Res
 31,
 1899-1908
 (2016).

 1036
 https://doi.org:10.1002/jbmr.2868
- 1037 87. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nature* 1038 *methods* 9, 676-682 (2012). https://doi.org:10.1038/nmeth.2019
- 1039 88. Kaji, H., Sugimoto, T., Kanatani, M., Nishiyama, K. & Chihara, K. Dexamethasone
 1040 stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells
 1041 and enhances osteoclast-like cell formation stimulated by parathyroid hormone and
- 1044 89. Marino, S., Logan, J. G., Mellis, D. & Capulli, M. Generation and culture of osteoclasts.
 1045 Bonekey Rep 3, 570 (2014). https://doi.org:10.1038/bonekey.2014.65
- 1046 90. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15-21
 1047 (2013). https://doi.org:10.1093/bioinformatics/bts635
- 1048 91. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high1049 throughput sequencing data. *Bioinformatics* 31, 166-169 (2015).
 1050 https://doi.org:10.1093/bioinformatics/btu638
- 1051

1053 ACKNOWLEDGMENTS

1054 We thank ML. Aknin (IPSIT, Facility PLAIMMO, Orsay), F. Mercier-Nomé (IPSIT, Facility 1055 PHIC, Orsay), Drs. V. Parietti-Montcuquet, C. Doliger, S. Duchez and N. Setterblad (Animal 1056 and Flow Cytometry Core Facilities, Institut de Recherche Saint-Louis, Paris), V. Nicolas 1057 (IPSIT, Facility MIPSIT, Orsay), D. Courilleau (IPSIT, Facility CIBLOT, Orsay) and C. 1058 Cordier and J. Megret (Plateau technique de cytométrie, SFR Necker, Paris) for their technical 1059 assistance. We thank the Montpellier Preclinical Platform of the Research Infrastructure 1060 ECELLFRANCE for the microCT analyses as well as the Plateforme d'Irradiation (IRSN, 1061 Fontenay-Aux-Roses, France) for their technical assistance. The study was supported by the 1062 LabEx LERMIT supported by ANR grant ANR-10-LABX-33 under the Program 1063 "Investissements d'Avenir" ANR-11-IDEX-0003-01, an ANR PRC grant (ANR-17-CE14-1064 0019) to M.A-L., C.B-W. and coordinated by K.B. and by the Association Saint Louis pour la 1065 Recherche sur les Leucémies to KB. J.N. was a PhD fellow from the DIM Cancéropôle and the 1066 FRM. Z.A-N. was a fellowship recipient from the French Ministry and from the FRM 1067 (FDT202204015088). V.R. was supported by the FRM, La Ligue Contre le Cancer and la 1068 Société Française d'Hématologie. A.Bon. was supported by an ANR @RAction grant (ANR-1069 14-ACHN-0008) and by a JCJC ANR grant (ANR-19-CE15-0019-01) to ME. A.Bou. was 1070 supported by the ANR grant 17-CE14-0019. J.L. was recipient from the People Program (Marie 1071 Curie Actions) of the European Union's Seventh Framework Program (FP7/2007-2013) under 1072 REA grant agreement n. PCOFUND-GA-2013-609102, through the PRESTIGE Program 1073 coordinated by Campus France, and from an ANR grant (ANR-17-CE14-0019). V.B., N.D. and 1074 K.B. were supported by the INCa agency under the program PRT-K 2017. J.K. was supported 1075 by European Union's Horizon 2020 MSCA, Program under grant agreement 641833 1076 (ONCORNET). D.H.M and P.M.M. were supported by the Division of Intramural Research of 1077 the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

- 1078 Graphical abstract and mouse icons were created using the Biorender software 1079 (Biorender.com).
- 1080

1081 AUTHOR CONTRIBUTIONS

- 1082 A.A., J.N. and Z.A-N. designed and performed experiments, analyzed data and contributed to
- 1083 manuscript writing; V.R., A.Bon., M.K., A.Bou., J.L., V.B., J.K., L.S., A.P. and A.C. performed
- 1084 experiments and analyzed data; S.P., N.D., M.A-L., S.J.C.M., G.L., F.G., C.B-W. and M.C-S.
- 1085 performed experiments, contributed to data analyses and reviewed the manuscript; D.H.M. and
- 1086 P.M.M provided WS samples and clinical data and reviewed the manuscript; M.E. and M.R.
- 1087 helped with the study design, performed experiments, contributed to data analyses and reviewed
- 1088 the manuscript; K.B. conceived, designed and supervised the study, contributed to data
- 1089 analyses, found funding for the study, and wrote the manuscript.
- 1090

1091 **COMPETING INTERESTS**

- 1092 The authors declare no competing interests.
- 1093

TABLES

	Gender	Chronic	Lumbar	Femoral
	Gender	treatment	spine	neck
P1	Female	No	- <i>3.1</i> ⁽⁵⁾	0
P2	Female	No	-1.1	-1.8
P3 ⁽¹⁾	Male	Yes ⁽²⁾	-1.8	-2.3
P4	Female	Yes ⁽³⁾	-2.7	-1.3
P5 ⁽¹⁾	Male	Yes ⁽⁴⁾	-1.8	-2.2

Table 1: Abnormal bone mineral density values in WS patients. Characteristics of each patient with low BMD value are shown. Four patients carry the CXCR4^{R334X} mutation and one displays the CXCR4^{S338X} mutation. There were 3 women and 2 men with an average age of 33.2 years (range 13-52). T-scores for lumbar spine (L1-L4) and femoral neck have been evaluated. According to World Health Organization (WHO) criteria, values classify patients as osteopenic with a T-score between -1.0 and -2.5 or osteoporotic with a T-score at or below -2.5. ⁽¹⁾For patients 3 and 5, because of their young age, Z-scores are given with a value at or below -2.0 considered as abnormal; ⁽²⁾G-CSF since age of 2; ⁽³⁾G-CSF several years at the time of scan; ⁽⁴⁾G-CSF for 6 months at the time of scan; ⁽⁵⁾Values outside the normal range defined by WHO are italicized.

1112 FIGURE LEGENDS

1113 Figure 1: WS-linked Cxcr4 mutations are associated with reduced bone mass in mice. (A) 1114 The bone mineral density (BMD) of lumbar spine of WT, +/1013 and 1013/1013 mice was 1115 measured through Dual-energy x-ray absorptiometry. Results represent means + SEM with 5 1116 mice per group examined over two independent experiments. Statistics were calculated with the nonparametric Kruskal–Wallis H test (##p=0.0042) and the nonparametric Mann–Whitney 1117 1118 test, two-sided, +/1013 p=0.0556, 1013/1013 **p=0.0079. (**B-D**) 3D representative images of 1119 trabecular and cortical composites (B) and quantitative μ CT analyses of trabecular (C) and 1120 cortical (D) parameters of femurs from WT and mutant mice. BV = bone volume; TV =1121 trabecular volume; Tb.Nb = trabecular number; Tb.Sp = trabecular separation; Ct.BV = cortical 1122 bone volume; Ct.Th = cortical thickness. Data (means + SEM) are from three independent1123 experiments with n=15, 15, and 7 mice in total for WT, +/1013 and 1013/1013 groups, 1124 respectively. Statistics were calculated with the nonparametric Kruskal-Wallis H test 1125 (###p=0.0007, BV/TV; p=0.0001, Tb.Nb; p<0.0001, Tb.Sp; Ct.BV, ##p=0.0072; #p=0.0241) and 1126 the unpaired two-tailed Student's t test (+/1013 vs WT **p=0.0556, 1013/1013 vs WT 1127 ***p=0.0005, +/1013 vs 1013/1013 §p=0.032 for BV/TV; ***p=0.0005, ***p<0.0001, 1128 ^{§§}p=0.008 for Tb.Nb; ***p=0.0038, ***p<0.0001, ^{§§§} p<0.0001 for Tb.Sp; **p=0.0072, **p=0.0078 for Ct.BV; *p=0.0147, *p=0.02 for Ct.Th). (E) BM sections were stained with 1129 1130 toluidine blue. Larger images show 2X inserts in trabecular areas. Bars: 200 µm. Images are 1131 representative of at least three independent determinations. (F) BM sections were 1132 immunostained for osteopontin (Opn) in association with DAPI. Trabeculae are indicated by 1133 white arrows. Bars: 250 µm. Images are representative of five independent determinations. (G 1134 and H) BM sections were stained for chondrocyte (alcian blue, G) or adipocyte (perilipin, H) 1135 markers. Bars: 500 (G) or 20 (H) µm. Images are representative of at least six independent 1136 determinations. (I) Cartilaginous growth plates were evaluated based on overall growth plate

1137 thickness measured on μ CT scans. Data (means + SEM) are from 2 independent experiments 1138 with n=7, 8, and 7 mice in total for WT, +/1013 and 1013/1013 groups, respectively. (J) 1139 Adipocyte counts were evaluated on perilipin-stained BM sections. Six fields of 3 mm² were 1140 analyzed per section. Results (means \pm SEM) are from 4 independent experiments with 13 mice 1141 in total per group. (K) Size (left) and weight (right) of WT and mutant mice. Results (means + 1142 SEM) are from five independent experiments with n=6, 9, and 10 mice in total for WT, +/10131143 and 1013/1013 groups, respectively. Mice were littermates, females and age-matched (8-12 wk-1144 old) in A-J and at 8 weeks of age in K. Source data are provided as a Source Data file.

Figure 2: Reduction of skeletal stromal cells in *Cxcr4*¹⁰¹³-bearing mice. (A) Representative 1146 1147 dot-plots showing the flow cytometric gating strategies used to sort stroma cells (CD45-1148 TER119⁻), differentiated osteoblast progenitor cells (OPCs, CD45⁻TER119⁻CD31⁻Sca-1⁻ 1149 $CD51^+PDGFR\alpha^{+/-}$ and SSCs (CD45⁻TER119⁻CD31⁻Sca-1⁺CD51⁺PDGFR\alpha⁺) in the mouse 1150 bone fraction. (B) Absolute numbers of the indicated stroma cell subsets from bone fractions 1151 were determined by flow cytometry. Data (means + SEM) are from at least six independent 1152 experiments with n=31, 31, and 17 mice in total for WT, +/1013 and 1013/1013 groups, 1153 respectively. Statistics were calculated with the nonparametric Kruskal-Wallis H test (###p<0.0001, OPC) and the unpaired two-tailed Student's t test (1013/1013 vs WT *p=0.0206 1154 for SSC; +/1013 vs WT **p=0.0031, 1013/1013 vs WT ***p<0.0001, +/1013 vs 1013/1013 1155 1156 p=0.0217 for OPC). (C) Schematic diagram for the generation of CD45.1 \rightarrow CD45.2 short (3) 1157 wks)- or long (16 wks)-term BM chimeras. (D) Proportions of WT donor CD45.1⁺ LSK SLAM 1158 and leukocytes (Leuko.) recovered from the BM and blood of BM chimeras in CD45.2⁺ WT or 1159 mutant recipients 16 weeks after transplantation. (E) Absolute numbers of SSCs and OPCs 1160 determined by flow cytometry in bone fractions of BM chimeras in CD45.2⁺ recipients. Data 1161 (means + SEM) in D and E are from three independent experiments with n = 10 (D) or 11 (E),

1162 9, and 5 mice in total for WT, +/1013 and 1013/1013 recipient groups, respectively. Statistics 1163 were calculated with the nonparametric Kruskal-Wallis H test (##p=0.0064) and the 1164 nonparametric Mann-Whitney test, two-sided (+/1013 vs WT **p=0.0042, 1013/1013 vs WT 1165 *p=0.0126, for SSC; +/1013 vs WT **p=0.0031, 1013/1013 vs WT *p=0.0398, for OPC). (F) 1166 Sixteen weeks after transplantation, BM sections from WT or mutant CD45.2⁺ recipient mice 1167 were immuno-stained for Opn in association with DAPI (bars: 250 µm). Trabeculae are 1168 indicated by white arrows. Images are representative of at least three independent 1169 determinations. (G) Left: Proportions of WT donor CD45.1⁺ LSK SLAM and leukocytes 1170 recovered from the BM and blood of BM chimeras in CD45.2⁺ WT or mutant recipients 3 weeks 1171 after transplantation. Right: Absolute numbers of SSCs and OPCs. Data (means + SEM) are 1172 from three independent experiments with n=9, 9, and 5 mice in total for WT, +/1013 and 1173 1013/1013 recipient groups, respectively, except for blood chimerism analysis (5 mice per 1174 group). Statistics were calculated with the nonparametric Kruskal–Wallis H test ([#]p=0.0327) 1175 and the nonparametric Mann–Whitney test, two-sided (1013/1013 vs WT *p=0.019, +/1013 vs 1176 1013/1013 §p=0.019 for SSC; 1013/1013 vs WT *p=0.017 for OPC). (H and I) 3D 1177 representative images of trabecular composites (H) and μ CT analyses of trabecular parameters 1178 (I) of femurs from WT BM-chimeric CD45.2⁺ WT or mutant recipients 4 months after 1179 transplantation. Data (means + SEM) are from three independent experiments with n= 8, 5, and 1180 5 mice in total for WT, +/1013 and 1013/1013 recipient groups, respectively. Statistics were 1181 calculated with the unpaired two-tailed Student's t test (+/1013 vs WT *p=0.033, 1013/1013 vs 1182 WT *p=0.024 for BV/TV). WT and mutant mice were littermates, females and age-matched 1183 (8-12 wk-old) and adult Boy/J (CD45.1) WT mice at 8 weeks of age were used as BM donors. 1184 Source data are provided as a Source Data file.

1186	Figure 3: Cell-extrinsic Cxcr4-mediated regulation of the skeletal landscape. (A)
1187	Schematic diagram for the generation of CD45.2→CD45.1 short (3 wks)- or long (16 wks)-
1188	term BM chimeras. (B) Proportions of WT or mutant donor CD45.2+ LSK SLAM and
1189	leukocytes recovered from the BM and blood of BM chimeras in CD45.1 ⁺ WT recipients 16
1190	weeks after transplantation. Statistics were calculated with the nonparametric Kruskal-Wallis
1191	H test (###p=0.0008 for SLAM and <0.0001 for Leukocytes) and the unpaired two-tailed
1192	Student's t test (+/1013 vs WT **p=0.0036, 1013/1013 vs WT ***p=0.0004, for SLAM;
1193	+/1013 vs WT ***p=0.0003, 1013/1013 vs WT ***p<0.0001, for Leukocytes). (C) Absolute
1194	numbers of SSCs and OPCs in bone fractions of BM chimeras in CD45.1 ⁺ recipients. Statistics
1195	were calculated with the nonparametric Kruskal–Wallis H test ($^{\#\#}p=0.009$ for SSC and $^{\#\#\#}p$
1196	=0.0006) and the unpaired two-tailed Student's t test (1013/1013 vs WT **p=0.0012, +/1013
1197	vs 1013/1013 §§p=0.0076, for SSC; +/1013 vs WT *p=0.029, 1013/1013 vs WT ***p<0.0001,
1198	+/1013 vs 1013/1013 §p=0.022, for OPC). Data (means \pm SEM) in B and C are from three
1199	independent experiments with $n= 14$ mice in total for WT, +/1013 and 1013/1013 donor groups,
1200	respectively, except for blood chimerism analysis ($n=11, 9$, and 8 mice in total for WT, +/1013
1201	and 1013/1013 donor groups, respectively). (D) Sixteen weeks after transplantation, BM
1202	sections from WT CD45.1 ⁺ recipient mice were immunostained for Opn in association with
1203	DAPI (bars: 250 μ m). Trabeculae are indicated by white arrows. Images are representative of
1204	at least three independent determinations. (E) Left: Proportions of WT or mutant donor
1205	CD45.2 ⁺ LSK SLAM and leukocytes recovered from the BM and blood of BM chimeras in
1206	CD45.1 ⁺ WT recipients 3 weeks after transplantation. Right: Absolute numbers of SSCs and
1207	OPCs. Data (means \pm SEM) are from three independent experiments with n= 6 (SLAM) or 7
1208	(SSC and OPC), 10, and 8 mice in total for WT, +/1013 and 1013/1013 donor groups,
1209	respectively, except for blood chimerism analysis ($n= 6, 5$, and 4 mice in total for WT, +/1013
1210	and 1013/1013 donor groups, respectively). Statistics were calculated with the nonparametric

1211 Kruskal–Wallis H test (##p=0.0083 for leukocytes; #p=0.047 for SSC; #p=0.018 for OPC) and 1212 the unpaired two-tailed Student's t test (+/1013 vs WT *p=0.021, 1013/1013 vs WT 1213 **p=0.0014, for leukocytes; +/1013 vs WT *p=0.046, 1013/1013 vs WT *p=0.029, for SSC; 1214 +/1013 vs WT *p=0.034, 1013/1013 vs WT *p=0.01, for OPC). (F-I) 3D representative images 1215 of trabecular or cortical composites (F and H) and µCT analyses of trabecular or cortical 1216 parameters (G and I) of femurs from WT or mutant BM-chimeric CD45.1⁺ WT recipients 4 1217 months after transplantation. Ct.BV = cortical bone volume; Ct.Th = cortical thickness. Data1218 (means + SEM) in G and I are from two independent experiments with n=5, 5, and 4 mice in 1219 total for WT, +/1013 and 1013/1013 donor groups, respectively. Statistics were calculated with 1220 the nonparametric Kruskal–Wallis H test (##p=0.0085 for BV/TV; ##p=0.0069 for Tb.Nb; 1221 ###p=0.0001 for Tb.Sp; #p=0.033 for Ct.BV) and the unpaired two-tailed Student's t test 1222 (1013/1013 vs WT *p=0.028, +/1013 vs 1013/1013 §p=0.028 for BV/TV; 1013/1013 vs WT *p=0.011, +/1013 vs 1013/1013 ^{§§}p=0.0088 for Tb.Nb; +/1013 vs WT *p=0.044, 1013/1013 vs 1223 1224 WT ***p<0.0001, +/1013 vs 1013/1013 §§§p=0.0006 for Tb.Sp; 1013/1013 vs WT *p=0.014, 1225 +/1013 vs 1013/1013 §p=0.016 for Ct.BV). Donor WT and mutant mice and Boy/J (CD45.1) 1226 WT recipient mice were females at 8 weeks of age. Source data are provided as a Source Data 1227 file.

Figure 4: Increased bone resorption and reduced bone formation in *Cxcr4¹⁰¹³*-bearing mice. (A) Bone sections were stained for Tartrate Resistant Acid Phosphatase (TRAP) activity (bars: 100 μ m). OCLs are visualized as brown-stained TRAP-positive cells attached to bone trabeculae and are indicated by arrows (representative images). (B) OCLs were quantified (Oc.S/BS) and (Oc.N/BV). Results represent means <u>+</u> SEM with 6 mice in total per group over 3 independent experiments. Statistics were calculated with the nonparametric Kruskal–Wallis H test (###p=0.0006) and the unpaired two-tailed Student's t test (1013/1013 vs WT *p=0.012

1236 for Oc.S/BS; 1013/1013 vs WT *p=0.049 for Oc.N/BV). (C and D) Dynamic 1237 histomorphometric measures of bone formation. OS/BS = Osteoid number / Bone surface; 1238 Obl.S/BS = Osteoblast surface / Bone surface; MS/BS = Mineralized surface / Bone surface; 1239 Dbl/BS = Double labelled surface / Bone surface. Data (means + SEM) are from 3 independent 1240 experiments with n=6, 6, and 5 mice in total for WT, +/1013 and 1013/1013 groups respectively 1241 in C, and n= 6, 6, and 5 (for MS/BS) or 6 (for Dbl/BS) mice in total for WT, +/1013 and 1242 1013/1013 groups respectively in D. Statistics were calculated with the nonparametric Kruskal-1243 Wallis H test (#p=0.038) and the unpaired two-tailed Student's t test (1013/1013 vs WT 1244 **p=0.0097 for MS/BS; 1013/1013 vs WT *p=0.035 for Dbl/BS). (E) The mineral apposition 1245 rate (MAR) and bone formation rate (BFR/BS) were determined. Results (means + SEM) are 1246 from 3 independent experiments with n=6, 6, and 5 (for MAR) or 6 (for BFR/BS) mice in total for WT, +/1013 and 1013/1013 groups respectively. Statistics were calculated with the 1247 1248 nonparametric Kruskal–Wallis H test (#p=0.039) and the unpaired two-tailed Student's t test 1249 (1013/1013 vs WT *p=0.03, +/1013 vs 1013/1013 [§]p=0.044). (F) Volcano plot analysis of 1250 differentially expressed genes obtained by RNA-seq between WT and 1013/1013 OPCs 1251 $(p<0.05; FC\geq2)$ performed on three biological replicates per group with one replicate 1252 representing the pool of 3 mice. Data represent analysis of cpm estimates with a log of fold 1253 change of more than 1.5 fold and p<0.05 using enhanced Volcano package. (G and J) Heatmap 1254 representing the relative expression levels of selected genes (osteogenic, G and 1255 osteoclastogenic, J) expressed by sorted OPCs. (H and K) Normalized counts of osteogenic 1256 (H) and osteoclastogenic (K) genes using the DESeq2 method. Data are represented as floating 1257 bars (min to max and line equal median) of the three biological replicates per group. For 1258 significance testing, DESeq2 uses a Wald test (p values). The Wald test P values from the subset 1259 of genes that pass an independent filtering step, are adjusted for multiple testing using the 1260 procedure of Benjamini and Hochberg (padj values). (I) In vitro osteoblastic differentiation of 1261 sorted OPCs evaluated at day 21 post-culture by Alizarin Red S coloration. The images are 1262 representative of 3 independent cultures. The quantification (means + SEM) from three 1263 independent experiments with 6 mice in total per group is shown. (L) In vitro expanded 1264 osteogenic cells from bone fractions were cultured with WT CD11b⁺ osteoclast progenitors and 1265 stimulated with PGE2/Vitamin D3 (VitD3)/Dexamethasone (Dex) for 8 days. OCLs (TRAP-1266 positive) were identified (left, representative images, bars: 100 µm) and quantified (right). Data 1267 (means + SEM) are from 2 independent experiments with 6 mice in total per group. Statistics 1268 were calculated with the nonparametric Kruskal–Wallis H test (#p=0.033) and the unpaired two-1269 tailed Student's t test (+/1013 vs WT *p=0.02 and 1013/1013 vs WT *p=0.014). (M) The 1270 relative expression levels of osteoclastogenic genes were determined by quantitative PCR in 1271 stimulated osteogenic cells (3 mice per group). Each individual sample was run in triplicate and 1272 has been standardized for 36B4 expression levels. All mice were littermates, females and age-1273 matched (8-12 wk-old). Source data are provided as a Source Data file.

Figure 5: Impaired osteogenic specification of Cxcr4¹⁰¹³-bearing skeletal stromal/stem 1275 1276 cells. (A) Ki-67 and DAPI co-staining to analyze by flow cytometry the cell cycle status of 1277 SSCs and OPCs from bone fractions. Bar graphs show the percentage of cells (DAPI^{low}Ki-67⁻) 1278 in the quiescent G0 phase. Data (means + SEM) are from three independent experiments with 1279 n=9, 6, and 6 mice in total for WT, +/1013 and 1013/1013 groups, respectively. Statistics were 1280 calculated with the nonparametric Kruskal-Wallis H test (#p=0.029) and the unpaired two-1281 tailed Student's t test (1013/1013 vs WT **p=0.0091). (B) Flow-cytometric detection of BrdU 1282 staining in SSCs (left). Percentages of BrdU⁺ bone SSCs and OPCs after a 12-day labelling 1283 period (right). Data (means + SEM) are from three independent experiments with six mice in 1284 total per group. Statistics were calculated with the nonparametric Kruskal-Wallis H test 1285 $(^{\text{##}p=0.0021})$ and the unpaired two-tailed Student's t test (+/1013 vs WT *p=0.016, 1013/1013)

1286 vs WT **p=0.0011). (C) Characterization of some biological processes displaying differential 1287 gene expression signatures in sorted SSCs as defined by GSEA and obtained by RNA-seq on 2 1288 (1013/1013) or 3 (WT and +/1013) biological replicates per group with one replicate 1289 representing the pool of 3 mice. For significance testing, DESeq2 uses a Wald test (p values). 1290 The Wald test P values from the subset of genes that pass an independent filtering step, are 1291 adjusted for multiple testing using the procedure of Benjamini and Hochberg (padj values). (D) 1292 RNA-seq-based heatmap representing the relative expression levels of osteogenic genes. (E) 1293 Normalized counts of selected osteogenic genes using the DESeq2 method. Data are 1294 represented as floating bars (min to max and line equal median) of the 2 or 3 biological 1295 replicates per group. For significance testing, DESeq2 uses a Wald test (p values). (F) The 1296 heatmap shows the relative expression levels (RQ) normalized for β -actin expression levels in 1297 each sample of selected genes involved in SSC differentiation towards the osteogenic lineage 1298 (6 pools of 100 cells per condition) by quantitative PCR. (G) RQ of the most regulated genes 1299 involved in differentiation and cell cycle of SSCs. Data (means + SEM) are from two 1300 independent experiments with 6 mice in total per group. Statistics were calculated with the 1301 nonparametric Kruskal–Wallis H test (#p=0.028 for Runx2; #p=0.011 for Ccnd3) and the 1302 unpaired two-tailed Student's t test (1013/1013 vs WT **p=0.0063 for Runx2; 1013/1013 vs 1303 WT *p=0.048 for *Coll a*; +/1013 vs WT *p=0.022 and 1013/1013 vs WT *p=0.02 for *Ccnd3*). 1304 (H) RNA-seq-based heatmap representing the relative expression levels of osteoclastogenic 1305 genes expressed by sorted SSCs. (I) Normalized counts of selected osteoclastogenic genes 1306 using the DESeq2 method. Data are represented as floating bars (min to max and line equal 1307 median) of the 2 or 3 biological replicates per group. For significance testing, DESeq2 uses a 1308 Wald test (p values). (J) Relative expression of osteoclastogenic genes in SSCs by quantitative 1309 PCR. Each individual sample was run in triplicate and has been standardized for β -actin 1310 expression levels and presented as relative expression to WT. Data (means + SEM) are from 1311 two independent experiments with 5 mice in total per group. (K) Immunofluorescence showing 1312 in red Osterix (Osx)-positive cells and in blue DAPI-stained nuclei in WT and mutant mice 1313 femurs (bars: 100 µm). Dashed lines indicate the limit between the cartilage growth plate (above 1314 the line) and the bone (below the line). Images are representative of at least 3 independent 1315 determinations. (L) Quantification of Osx⁺ cells per mm² below the growth plate. Data (means 1316 + SEM) are from 5, 5, and 3 independent mice in total for WT, +/1013 and 1013/1013 groups 1317 respectively. Statistics were calculated with the unpaired two-tailed Student's t test (1013/1013 1318 vs WT *p=0.0101). (M) Absolute numbers of the indicated stroma cell subsets from marrow 1319 fractions determined by flow cytometry. Data (means + SEM) are from four independent 1320 experiments with n=9, 10, and 7 mice in total for WT, +/1013 and 1013/1013 groups, 1321 respectively. Statistics were calculated with the nonparametric Kruskal-Wallis H test 1322 (###p=0.0004 for stroma; ##p=0.0013 for OPC) and the unpaired two-tailed Student's t test 1323 (+/1013 vs WT **p=0.0011, 1013/1013 vs WT ***p=0.0002, +/1013 vs 1013/1013 §p=0.033, for stroma; +/1013 vs WT **p=0.0049, 1013/1013 vs WT ***p=0.0003, for OPC). All mice 1324 1325 were littermates, females and age-matched (8-12 wk-old). Source data are provided as a Source 1326 Data file.

1327

1328 Figure 6: Cxcr4 desensitization intrinsically regulates in vitro the osteogenic 1329 differentiation of skeletal stromal cells. (A) Number of colonies formed from bone fractions 1330 in CFU-F assays. Data (means + SEM) are from two independent experiments with n = 4, 6, 1331 and 4 mice in total for WT, +/1013 and 1013/1013 groups respectively. Statistics were 1332 calculated with the nonparametric Kruskal-Wallis H test (##p=0.002) and the unpaired two-1333 tailed Student's t test (+/1013 vs WT *p=0.029, 1013/1013 vs WT ***p=0.0008). (B) After in vitro loading with BrdU (5 days) or CTV (3 days), the percentages of BrdU⁺ (left) or CTV^{low} 1334 1335 (right) cells within WT and mutant bone-derived SSCs were determined by flow cytometry.

1336 Data (means + SEM) are from 3 independent experiments with 6 mice in total per group. 1337 Statistics were calculated with the nonparametric Kruskal-Wallis H test (#p=0.0231 and 1338 ^{##}p=0.0047 for BrdU⁺ and CTV^{low} respectively) and the unpaired two-tailed Student's t test 1339 (+/1013 vs WT *p=0.031, 1013/1013 vs WT **p=0.0023 for BrdU⁺; +/1013 vs WT *p=0.015, 1340 1013/1013 vs WT **p=0.0054 for CTV^{low}). (C) Bar graphs show the percentages of cultured 1341 WT or mutant SSCs in the quiescent G0 phase (DAPI^{low}Ki-67⁻, left) or with an apoptotic 1342 phenotype (Annexin V^+ DAPI⁻, right) as determined by flow cytometry. Data (means + SEM) 1343 are from three (right panel) or five (left panel) independent SSC cultures per genotype. Statistics 1344 were calculated using the unpaired two-tailed Student's t test (+/1013 vs WT *p=0.032, 1345 1013/1013 vs WT *p=0.021). (**D**) Doubling time (left) and absolute numbers (right) of WT and 1346 mutant SSCs after 3 days of culture. Data (means + SEM) are from 8, 6, and 5 independent SSC 1347 cultures for WT, +/1013 and 1013/1013 groups respectively. Statistics were calculated using 1348 the unpaired two-tailed Student's t test (+/1013 vs WT *p=0.028, 1013/1013 vs WT *p=0.033 1349 for doubling-time; 1013/1013 vs WT *p=0.048 for SSC). (E) Alkaline phosphatase (Alp) 1350 staining was performed 14 days after initiation of the culture of WT and mutant SSCs in 1351 osteogenic medium supplemented every two days with 10 µM AMD3100 or vehicle (PBS) 1352 (bars: 100 µm). Quantitative analyses (number of Alp⁺ cells) were performed under an inverted 1353 microscope. Data (means + SEM) are from 6 independent cultures per genotype. Statistics were calculated with the nonparametric Kruskal-Wallis H test (##p=0.0022) and the unpaired two-1354 1355 tailed Student's t test (+/1013 vs WT **p=0.0075, 1013/1013 vs WT **p=0.0018). (F) Alizarin 1356 Red staining was performed 21 days after initiation of the culture. Quantitative analyses (means 1357 + SEM) of staining were performed using the osteogenesis assay kit in 12 (vehicle) or 6 1358 (AMD3100) independent cultures per genotype. Statistics were calculated with the nonparametric Kruskal–Wallis H test (###p=0.0002) and the unpaired two-tailed Student's t test 1359 1360 (+/1013 vs WT ***p=0.0005, 1013/1013 vs WT ***p<0.0001). (G) Expression levels of 1361 osteogenic genes were determined by quantitative PCR in 6 independent WT and mutant SSC 1362 cultures 14 and 21 days after initiation of the osteogenic culture in the presence or absence of 1363 AMD3100. Each individual sample was run in triplicate and was standardized for β -actin 1364 expression levels. Results (means + SEM) are expressed as relative expression compared to 1365 WT samples. Statistics were calculated with the nonparametric Kruskal-Wallis H test 1366 (#p=0.038 and 0.0205 for Osx days 14 and 21 respectively; #p=0.024 and 0.015 for Alp days 14 1367 and 21 respectively; ##p=0.0063 for Opn days 21; #p=0.026 for Ocn days 21) and the unpaired 1368 two-tailed Student's t test (1013/1013 vs WT *p=0.0107 and 0.013 for Osx days 14 and 21 1369 respectively; 1013/1013 vs WT *p=0.035 and ***p=0.0001 for Alp days 14 and 21 1370 respectively; +/1013 vs WT *p=0.022 and 1013/1013 vs WT **p=0.0056 for Opn days 21; 1371 1013/1013 vs WT **p=0.0108 for Ocn days 21). All mice were littermates, females and age-1372 matched (8-12 wk-old). Source data are provided as a Source Data file.

1373

1374 **Figure 7:** Normalization of Cxcr4 signaling rescues the osteogenic properties of Cxcr4¹⁰¹³-

1375 bearing mouse skeletal cells. (A) Schematic diagram for daily AMD3100 intra-peritoneal 1376 (*i.p.*) injection for 21 days in WT and mutant mice. (B) Absolute numbers of the indicated 1377 stroma cell subsets from bone fractions of WT and mutant mice determined by flow cytometry. 1378 Data (means + SEM) are from 2 independent experiments with 6 PBS injected mice and 11 1379 AMD3100-injected mice in total per genotype. Statistics were calculated using the 1380 nonparametric Mann–Whitney test, two-sided, 1013/1013 vs WT *p=0.041, 1013/1013 (AMD) 1381 vs 1013/1013 (vehicle) &p=0.01 for SSC; 1013/1013 vs WT **p=0.0022, WT (AMD) vs WT 1382 (vehicle) ^{&&}p=0.0065, 1013/1013 (AMD) vs 1013/1013 (vehicle) ^{&&&}p=0.0003 for OPC. (C) 1383 BM sections from WT and mutant mice treated with vehicle (PBS) or AMD3100 were 1384 immunostained for Opn in association with DAPI. Bars: 500µm. Images are representative of 1385 3 independent determinations. (D) Bone mineral density (BMD) values of lumbar spine from 6 1386 treated mice in total per group are shown. Statistics were calculated using the nonparametric 1387 Mann-Whitney test, two-sided, +/1013 vs WT *p=0.041, 1013/1013 vs WT **p=0.0022, 1388 +/1013 (AMD) vs +/1013 (vehicle) ^{&&}p=0.0087, 1013/1013 (AMD) vs 1013/1013 (vehicle) 1389 [&]p=0.026. (E) Cortical thickness was measured in sections stained with Toluidine Blue. Both 1390 cortices were measured and data are presented as a mean of both cortices from 6 mice in total 1391 per group. Statistics were calculated using the nonparametric Mann-Whitney test, two-sided, 1392 1013/1013 vs WT **p=0.026. Data (means + SEM) displayed in D and E are from 2 1393 independent experiments. All mice were littermates, females and age-matched (8-12 wk-old). 1394 Source data are provided as a Source Data file.

1395

1396 Figure 8: BM stromal cells from WS patients displayed in vitro impaired osteogenic 1397 capacities. (A) Relative expression levels of osteogenic genes were determined by quantitative 1398 PCR at day 14 in osteogenic-induced cultures of two WS patients-derived BMSCs and 7 healthy 1399 donors-derived BMSCs. Each individual sample was run in triplicate and was standardized for 36B4 expression levels. Results (means \pm SEM) are expressed as relative expression compared 1400 1401 to healthy samples (set at 1 and representing the mean of the 7 healthy donors) and are from 2 1402 independent experiments. Statistics were calculated using the nonparametric Mann-Whitney 1403 test, two-sided, **p=0.0079 for OSX, RUNX2 and OCN; *p=0.0179 for OPN. (B) Alizarin 1404 Red staining was performed 21 days after initiation of the culture of 1.5×10^3 healthy or WS 1405 BMSCs in pro-osteogenic medium (left panel). Representative images for healthy (H) and WS 1406 donors #1 and #2 are shown. Quantitative analyses of staining (means \pm SEM) were performed 1407 using the osteogenesis assay kit in 3 independent cultures with 2 WS and 6 healthy donors (right 1408 panel). Statistics were calculated using the nonparametric Mann-Whitney test, two-sided, 1409 **p=0.0022 for healthy. (C) Oil Red O staining was performed 21 days after initiation of 1410 cultures of healthy or WS BMSCs in pro-adipogenic differentiation medium. Bars: 200µm. (D) Proposed model: Proper Cxcr4 signaling termination is essential for bone tissue homeostasis. Absence of Cxcr4 desensitization leads to imbalance in bone remodeling with decreased OBLmediated bone formation and increased OCL-mediated bone resorption, leading to severe trabecular and cortical alterations and a subsequent osteoporotic-like phenotype. Mechanistically, impaired Cxcr4 desensitization disrupts the osteogenic commitment of SSCs, while strikingly increasing their pro-osteoclastogenic capacities. Source data are provided as a Source Data file.






Figure 1








Figure 4

PGE2/VitD3/Dex







Figure 5







Adipogenic

